TW247275B - - Google Patents

Info

Publication number: TW247275B
Authority: TW; Taiwan
Prior art keywords: particles; methods; maintain; useful; particle size
Prior art date: 1991-01-25

Application number

TW081100510A

Other languages

Original Assignee

Sterling Winthrop Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-25

Filing date

1992-01-24

Publication date

1995-05-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24595721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW247275(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-01-24 Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc

1995-05-11 Application granted granted Critical

1995-05-11 Publication of TW247275B publication Critical patent/TW247275B/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0476—Particles, beads, capsules, spheres
- A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
- A61K49/049—Surface-modified nanoparticles, e.g. immune-nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
- A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Nanotechnology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Molecular Biology (AREA)
Crystallography & Structural Chemistry (AREA)
Dispersion Chemistry (AREA)
Medicinal Preparation (AREA)
Manufacturing Of Micro-Capsules (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Physical Or Chemical Processes And Apparatus (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Helmets And Other Head Coverings (AREA)
Professional, Industrial, Or Sporting Protective Garments (AREA)

TW081100510A 1991-01-25 1992-01-24 TW247275B (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/647,105 US5145684A (en)	1991-01-25	1991-01-25	Surface modified drug nanoparticles

Publications (1)

Publication Number	Publication Date
TW247275B true TW247275B (zh)	1995-05-11

Family

ID=24595721

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW081100510A TW247275B (zh)	1991-01-25	1992-01-24

Country Status (22)

Country	Link
US (1)	US5145684A (zh)
EP (1)	EP0499299B1 (zh)
JP (1)	JP3602546B2 (zh)
KR (1)	KR100200061B1 (zh)
AT (1)	ATE195416T1 (zh)
CA (1)	CA2059432C (zh)
DE (1)	DE69231345T2 (zh)
DK (1)	DK0499299T3 (zh)
ES (1)	ES2149164T3 (zh)
FI (1)	FI108333B (zh)
GR (1)	GR3034759T3 (zh)
HU (1)	HU221586B (zh)
IE (1)	IE920217A1 (zh)
IL (1)	IL100754A (zh)
MX (1)	MX9200291A (zh)
MY (1)	MY108134A (zh)
NO (1)	NO303668B1 (zh)
NZ (1)	NZ241362A (zh)
PT (1)	PT499299E (zh)
RU (1)	RU2066553C1 (zh)
SG (1)	SG55104A1 (zh)
TW (1)	TW247275B (zh)

Families Citing this family (1202)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5994041A (en) *	1985-04-06	1999-11-30	Eastman Kodak Company	Process for buffering concentrated aqueous slurries
US5552154A (en) *	1989-11-06	1996-09-03	The Stehlin Foundation For Cancer Research	Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5399363A (en) *	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
AU642066B2 (en) *	1991-01-25	1993-10-07	Nanosystems L.L.C.	X-ray contrast compositions useful in medical imaging
US5552160A (en) *	1991-01-25	1996-09-03	Nanosystems L.L.C.	Surface modified NSAID nanoparticles
SE9101090D0 (sv) *	1991-04-11	1991-04-11	Astra Ab	Process for conditioning of water-soluble substances
US5766635A (en) *	1991-06-28	1998-06-16	Rhone-Poulenc Rorer S.A.	Process for preparing nanoparticles
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5407659A (en) *	1991-10-22	1995-04-18	Mallinckrodt Medical, Inc.	Treated calcium/oxyanion-containing particles for medical diagnostic imaging
US5344640A (en) *	1991-10-22	1994-09-06	Mallinckrodt Medical, Inc.	Preparation of apatite particles for medical diagnostic imaging
US5342609A (en) *	1991-10-22	1994-08-30	Mallinckrodt Medical, Inc.	Microfluidization of calcium/oxyanion-containing particles
US5916540A (en) *	1994-10-24	1999-06-29	Glaxo Group Limited	Aerosol formulations containing P134A and/or P227 and particulate medicament
US7105152B1 (en)	1991-12-18	2006-09-12	3M Innovative Properties Company	Suspension aerosol formulations
US7101534B1 (en)	1991-12-18	2006-09-05	3M Innovative Properties Company	Suspension aerosol formulations
EP0617610B1 (en) *	1991-12-18	1997-03-19	Minnesota Mining And Manufacturing Company	Suspension aerosol formulations
US6080751A (en) *	1992-01-14	2000-06-27	The Stehlin Foundation For Cancer Research	Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
EP0644755B1 (en) *	1992-06-10	1997-03-19	NanoSystems L.L.C.	Surface modified nsaid nanoparticles
US5552156A (en) *	1992-10-23	1996-09-03	Ohio State University	Liposomal and micellular stabilization of camptothecin drugs
AU660852B2 (en) *	1992-11-25	1995-07-06	Elan Pharma International Limited	Method of grinding pharmaceutical substances
US5346702A (en) *	1992-12-04	1994-09-13	Sterling Winthrop Inc.	Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) *	1992-12-04	1994-03-29	Sterling Winthrop Inc.	Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) *	1992-12-09	1994-04-12	Sterling Winthrop Inc.	Method to reduce particle size growth during lyophilization
US5340564A (en) *	1992-12-10	1994-08-23	Sterling Winthrop Inc.	Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) *	1992-12-11	1994-08-09	Sterling Winthrop Inc.	Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) *	1992-12-15	1995-07-04	Eastman Kodak Company	Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5364550A (en) *	1992-12-16	1994-11-15	Eastman Kodak Company	Liquid detergent composition
US5256328A (en) *	1992-12-16	1993-10-26	Eastman Kodak Company	Liquid toilet bowl cleaner and sanitizer containing halogen donating nanoparticles
US5322679A (en) *	1992-12-16	1994-06-21	Sterling Winthrop Inc.	Iodinated aroyloxy esters
US5352459A (en) *	1992-12-16	1994-10-04	Sterling Winthrop Inc.	Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) *	1992-12-17	1994-07-05	Sterling Winthrop Inc.	Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5354564A (en) *	1992-12-18	1994-10-11	Eastman Kodak Company	Personal care compositions
US6491938B2 (en)	1993-05-13	2002-12-10	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en)	1993-01-28	1999-11-09	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en)	1993-01-28	2003-12-16	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6537579B1 (en)	1993-02-22	2003-03-25	American Bioscience, Inc.	Compositions and methods for administration of pharmacologically active compounds
US5916596A (en)	1993-02-22	1999-06-29	Vivorx Pharmaceuticals, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
FR2702160B1 (fr) *	1993-03-02	1995-06-02	Biovecteurs As	Vecteurs particulaires synthétiques et procédé de préparation.
US5830436A (en) *	1993-03-30	1998-11-03	Duke University	Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
US5849263A (en) *	1993-03-30	1998-12-15	Charlotte-Mecklenburg Hospital Authority	Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
US5840277A (en) *	1993-03-30	1998-11-24	Charlotte Hospital Authority	Treatment of chronic pulmonary inflammation
CH686761A5 (de)	1993-05-27	1996-06-28	Sandoz Ag	Galenische Formulierungen.
US5543158A (en) *	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
US5635206A (en) *	1994-01-20	1997-06-03	Hoffmann-La Roche Inc.	Process for liposomes or proliposomes
EP0678771B1 (en) *	1994-04-18	2001-11-21	Eastman Kodak Company	Stable aqueous solid particle dispersions
US5468598A (en) *	1994-04-18	1995-11-21	Eastman Kodak Company	Solid particle dispersions for imaging systems
US5500331A (en) *	1994-05-25	1996-03-19	Eastman Kodak Company	Comminution with small particle milling media
US5478705A (en) *	1994-05-25	1995-12-26	Eastman Kodak Company	Milling a compound useful in imaging elements using polymeric milling media
TW384224B (en) *	1994-05-25	2000-03-11	Nano Sys Llc	Method of preparing submicron particles of a therapeutic or diagnostic agent
US5513803A (en) *	1994-05-25	1996-05-07	Eastman Kodak Company	Continuous media recirculation milling process
US5587143A (en) *	1994-06-28	1996-12-24	Nanosystems L.L.C.	Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US6007845A (en) *	1994-07-22	1999-12-28	Massachusetts Institute Of Technology	Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5626862A (en) *	1994-08-02	1997-05-06	Massachusetts Institute Of Technology	Controlled local delivery of chemotherapeutic agents for treating solid tumors
US20110196039A9 (en) *	1994-10-05	2011-08-11	Kaesemeyer Wayne H	Controlled release arginine formulations
DE4440337A1 (de) *	1994-11-11	1996-05-15	Dds Drug Delivery Services Ges	Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5955108A (en) *	1994-12-16	1999-09-21	Quadrant Healthcare (Uk) Limited	Cross-linked microparticles and their use as therapeutic vehicles
US6524557B1 (en) *	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
US5609998A (en) *	1994-12-29	1997-03-11	Eastman Kodak Company	Process for dispersing concentrated aqueous slurries
US5585108A (en) *	1994-12-30	1996-12-17	Nanosystems L.L.C.	Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US20020048596A1 (en) *	1994-12-30	2002-04-25	Gregor Cevc	Preparation for the transport of an active substance across barriers
US5628981A (en) *	1994-12-30	1997-05-13	Nano Systems L.L.C.	Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5466440A (en) *	1994-12-30	1995-11-14	Eastman Kodak Company	Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5665331A (en) *	1995-01-10	1997-09-09	Nanosystems L.L.C.	Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5716642A (en) *	1995-01-10	1998-02-10	Nano Systems L.L.C.	Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5662883A (en) *	1995-01-10	1997-09-02	Nanosystems L.L.C.	Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) *	1995-01-10	1996-10-01	Nano Systems L.L.C.	Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) *	1995-01-24	1996-10-29	Nano Systems L.L.C.	Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5520904A (en) *	1995-01-27	1996-05-28	Mallinckrodt Medical, Inc.	Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
ATE198148T1 (de) *	1995-02-06	2001-01-15	Elan Pharma Int Ltd	Formulierungen von verbindungen als nanopartikel dispergiert in verdaubaren ölen oder fettsäuren
US5571536A (en) *	1995-02-06	1996-11-05	Nano Systems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5665330A (en) *	1995-02-08	1997-09-09	Nano Systems Llc	Dual purposed diagnostic/therapeutic agent having a tri-iodinated benzoyl group linked to a coumarin
US5503723A (en) *	1995-02-08	1996-04-02	Eastman Kodak Company	Isolation of ultra small particles
US5518738A (en) *	1995-02-09	1996-05-21	Nanosystem L.L.C.	Nanoparticulate nsaid compositions
US5622938A (en) *	1995-02-09	1997-04-22	Nano Systems L.L.C.	Sugar base surfactant for nanocrystals
US5591456A (en) *	1995-02-10	1997-01-07	Nanosystems L.L.C.	Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) *	1995-02-13	1996-11-12	Nano Systems L.L.C.	Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) *	1995-02-14	1996-04-23	Nanosystems Llc	Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) *	1995-02-14	1996-08-06	Nanosystems L.L.C.	Process of preparing x-ray contrast compositions containing nanoparticles
AU4867296A (en) *	1995-02-14	1996-09-04	Nanosystems L.L.C.	Process of preparing lymphography contrast agents
US5580579A (en) *	1995-02-15	1996-12-03	Nano Systems L.L.C.	Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
ATE274341T1 (de) *	1995-02-24	2004-09-15	Elan Pharma Int Ltd	Nanopartikel-dispersionen enthaltende aerosole
US5565188A (en) *	1995-02-24	1996-10-15	Nanosystems L.L.C.	Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en) *	1995-02-24	1998-05-05	Nanosystems, L.L.C.	Aerosols containing beclomethazone nanoparticle dispersions
US5736156A (en) *	1995-03-22	1998-04-07	The Ohio State University	Liposomal anf micellular stabilization of camptothecin drugs
US5605696A (en) *	1995-03-30	1997-02-25	Advanced Cardiovascular Systems, Inc.	Drug loaded polymeric material and method of manufacture
US6428771B1 (en) *	1995-05-15	2002-08-06	Pharmaceutical Discovery Corporation	Method for drug delivery to the pulmonary system
IL118088A0 (en) *	1995-06-07	1996-08-04	Anzon Inc	Colloidal particles of solid flame retardant and smoke suppressant compounds and methods for making them
EP0752245B1 (en) *	1995-07-05	2002-05-22	European Community	Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery
BE1009856A5 (fr)	1995-07-14	1997-10-07	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6290969B1 (en) *	1995-09-01	2001-09-18	Corixa Corporation	Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en)	1995-09-01	2002-10-01	Corixa Corporation	Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) *	1995-09-01	2003-07-15	Corixa Corporation	Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6391338B1 (en) *	1995-09-07	2002-05-21	Biovail Technologies Ltd.	System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5834025A (en)	1995-09-29	1998-11-10	Nanosystems L.L.C.	Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6576264B1 (en)	1995-10-17	2003-06-10	Skyepharma Canada Inc.	Insoluble drug delivery
US5679138A (en) *	1995-11-30	1997-10-21	Eastman Kodak Company	Ink jet inks containing nanoparticles of organic pigments
US5662279A (en) *	1995-12-05	1997-09-02	Eastman Kodak Company	Process for milling and media separation
US20050267302A1 (en) *	1995-12-11	2005-12-01	G.D. Searle & Co.	Eplerenone crystalline form exhibiting enhanced dissolution rate
US5968543A (en) *	1996-01-05	1999-10-19	Advanced Polymer Systems, Inc.	Polymers with controlled physical state and bioerodibility
US5686133A (en) *	1996-01-31	1997-11-11	Port Systems, L.L.C.	Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
NZ331460A (en) *	1996-03-05	1998-12-23	Acusphere Inc	Microencapsulated fluorinated gases for use as imaging agents
US5611344A (en) *	1996-03-05	1997-03-18	Acusphere, Inc.	Microencapsulated fluorinated gases for use as imaging agents
AU702955B2 (en) *	1996-05-17	1999-03-11	Quadrant Healthcare (Uk) Limited	Microparticles and their use in wound therapy
US6254854B1 (en)	1996-05-24	2001-07-03	The Penn Research Foundation	Porous particles for deep lung delivery
EP0914102B8 (en)	1996-05-24	2005-11-02	Angiotech Pharmaceuticals, Inc.	Compositions and methods for treating or preventing diseases of body passageways
US5874064A (en)	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en)	1996-05-24	2001-02-13	Massachusetts Institute Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US20020052310A1 (en) *	1997-09-15	2002-05-02	Massachusetts Institute Of Technology The Penn State Research Foundation	Particles for inhalation having sustained release properties
US6652837B1 (en) *	1996-05-24	2003-11-25	Massachusetts Institute Of Technology	Preparation of novel particles for inhalation
US6503480B1 (en) *	1997-05-23	2003-01-07	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US5726154A (en) *	1996-06-28	1998-03-10	University Of Utah Research Foundation	Stabilization and oral delivery of calcitonin
US5837221A (en) *	1996-07-29	1998-11-17	Acusphere, Inc.	Polymer-lipid microencapsulated gases for use as imaging agents
US5935890A (en)	1996-08-01	1999-08-10	Glcc Technologies, Inc.	Stable dispersions of metal passivation agents and methods for making them
US6465016B2 (en)	1996-08-22	2002-10-15	Research Triangle Pharmaceuticals	Cyclosporiine particles
US7255877B2 (en) *	1996-08-22	2007-08-14	Jagotec Ag	Fenofibrate microparticles
US7060253B1 (en) *	1996-09-20	2006-06-13	Mundschenk David D	Topical formulations and delivery systems
GB9622173D0 (en) *	1996-10-24	1996-12-18	Glaxo Group Ltd	Particulate Products
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
FR2758459B1 (fr) *	1997-01-17	1999-05-07	Pharma Pass	Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6416778B1 (en)	1997-01-24	2002-07-09	Femmepharma	Pharmaceutical preparations and methods for their regional administration
US5993856A (en) *	1997-01-24	1999-11-30	Femmepharma	Pharmaceutical preparations and methods for their administration
WO1998035666A1 (en) *	1997-02-13	1998-08-20	Nanosystems Llc	Formulations of nanoparticle naproxen tablets
US6045829A (en) *	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
CO4920215A1 (es) *	1997-02-14	2000-05-29	Novartis Ag	Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US20050004049A1 (en) *	1997-03-11	2005-01-06	Elan Pharma International Limited	Novel griseofulvin compositions
CA2230748C (en) *	1997-03-14	2010-08-03	American Home Products Corporation	Rapamycin formulations for oral administration
US5989591A (en) *	1997-03-14	1999-11-23	American Home Products Corporation	Rapamycin formulations for oral administration
US6193954B1 (en) *	1997-03-21	2001-02-27	Abbott Laboratories	Formulations for pulmonary delivery of dopamine agonists
WO1998047492A1 (en) *	1997-04-18	1998-10-29	Vertex Pharmaceuticals Incorporated	Nanosized aspartyl protease inhibitors
AU732455C (en)	1997-05-08	2002-09-05	Merck Sharp & Dohme Limited	Substituted 1,2,4-triazolo{3,4-a}phthalazine derivatives as gaba alpha 5 ligands
IT1292142B1 (it) *	1997-06-12	1999-01-25	Maria Rosa Gasco	Composizione farmaceutica in forma di microparticelle lipidiche solide atte alla somministrazione parenterale
WO1998057648A1 (en) *	1997-06-16	1998-12-23	Vertex Pharmaceuticals Incorporated	Methods of increasing the bioavailability of stable crystal polymorphs of a compound
PT1023050E (pt) *	1997-06-27	2013-12-04	Abraxis Bioscience Llc	Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
SG165156A1 (en)	1997-06-27	2010-10-28	Abraxis Bioscience Llc	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
UA62983C2 (en) *	1997-09-12	2004-01-15		Pharmaceutical composition for treating or preventing dysmenorrhea or premature labor
US7052678B2 (en)	1997-09-15	2006-05-30	Massachusetts Institute Of Technology	Particles for inhalation having sustained release properties
US6946117B1 (en) *	1997-09-29	2005-09-20	Nektar Therapeutics	Stabilized preparations for use in nebulizers
US20020017295A1 (en) *	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en)	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US6919070B1 (en) *	1997-10-17	2005-07-19	Zakrytoe Aktsionernoe Obschestvo “OSTIM”	Stomatic composition
UA72189C2 (uk) *	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
GB9726543D0 (en) *	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel compositions
US6086376A (en) *	1998-01-30	2000-07-11	Rtp Pharma Inc.	Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
YU46500A (sh)	1998-02-25	2002-11-15	Merck Charp & Dohme Limited	Substituisani 1,2,4-triazolo /3,4-a/piridazin
US6287693B1 (en) *	1998-02-25	2001-09-11	John Claude Savoir	Stable shaped particles of crystalline organic compounds
ZA991922B (en) *	1998-03-11	1999-09-13	Smithkline Beecham Corp	Novel compositions of eprosartan.
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
DE69929959T2 (de) *	1998-03-30	2006-11-02	Jagotec Ag	Zubereitungen enthaltend mikropartikel von wasserunlöslichen substanzen, sowie verfahren zu deren herstellung
US6337092B1 (en)	1998-03-30	2002-01-08	Rtp Pharma Inc.	Composition and method of preparing microparticles of water-insoluble substances
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
ES2216517T3 (es)	1998-05-29	2004-10-16	Skyepharma Canada Inc.	Composiciones de microcapsulas termoprotegidas y procedimiento para su esterilizacion terminal con vapor.
US6153225A (en) *	1998-08-13	2000-11-28	Elan Pharma International Limited	Injectable formulations of nanoparticulate naproxen
CN1221249C (zh)	1998-08-19	2005-10-05	斯凯伊药品加拿大公司	普鲁泊福的可注射水分散体
US6956021B1 (en)	1998-08-25	2005-10-18	Advanced Inhalation Research, Inc.	Stable spray-dried protein formulations
US6165506A (en) *	1998-09-04	2000-12-26	Elan Pharma International Ltd.	Solid dose form of nanoparticulate naproxen
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
JP2002525311A (ja) *	1998-10-01	2002-08-13	エランファーマインターナショナル，リミティド	徐放性ナノ粒子組成物
US20040013613A1 (en) *	2001-05-18	2004-01-22	Jain Rajeev A	Rapidly disintegrating solid oral dosage form
US8293277B2 (en) *	1998-10-01	2012-10-23	Alkermes Pharma Ireland Limited	Controlled-release nanoparticulate compositions
US8236352B2 (en) *	1998-10-01	2012-08-07	Alkermes Pharma Ireland Limited	Glipizide compositions
US20080213378A1 (en) *	1998-10-01	2008-09-04	Elan Pharma International, Ltd.	Nanoparticulate statin formulations and novel statin combinations
US20090297602A1 (en) *	1998-11-02	2009-12-03	Devane John G	Modified Release Loxoprofen Compositions
US20070160675A1 (en) *	1998-11-02	2007-07-12	Elan Corporation, Plc	Nanoparticulate and controlled release compositions comprising a cephalosporin
CA2653839A1 (en) *	1998-11-02	2000-05-11	John G. Devane	Multiparticulate modified release composition
US6428814B1 (en)	1999-10-08	2002-08-06	Elan Pharma International Ltd.	Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6969529B2 (en) *	2000-09-21	2005-11-29	Elan Pharma International Ltd.	Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US7521068B2 (en) *	1998-11-12	2009-04-21	Elan Pharma International Ltd.	Dry powder aerosols of nanoparticulate drugs
US6375986B1 (en)	2000-09-21	2002-04-23	Elan Pharma International Ltd.	Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
PT1131070E (pt) *	1998-11-12	2008-11-19	Smithkline Beecham Plc	Composição farmacêutica para libertação modificada de um sensibilizador à insulina e de outro agente antidiabético
GB9824897D0 (en)	1998-11-12	1999-01-06	Merck Sharp & Dohme	Therapeutic compounds
BR9915738A (pt)	1998-11-20	2001-10-02	Rtp Pharma Inc	Micropartìculas estabilizadas em fosfolipìdeos dispersìveis
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
US6395511B1 (en) *	1998-11-27	2002-05-28	Darwin Discovery, Ltd.	Nucleic acids encoding a novel family of TGF-β binding proteins from humans
DE19856432A1 (de) *	1998-12-08	2000-06-15	Basf Ag	Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
ES2173679T3 (es)	1999-01-27	2002-10-16	Idea Ag	Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
PT1031346E (pt)	1999-01-27	2002-09-30	Idea Ag	Vacinacao nao invasiva atraves da pele
US6761903B2 (en)	1999-06-30	2004-07-13	Lipocine, Inc.	Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US7374779B2 (en) *	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6267985B1 (en) *	1999-06-30	2001-07-31	Lipocine Inc.	Clear oil-containing pharmaceutical compositions
US6294192B1 (en)	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6270806B1 (en) *	1999-03-03	2001-08-07	Elan Pharma International Limited	Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) *	1999-03-08	2001-07-31	Klan Pharma International Ltd.	Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
EG23951A (en)	1999-03-25	2008-01-29	Otsuka Pharma Co Ltd	Cilostazol preparation
US6383471B1 (en)	1999-04-06	2002-05-07	Lipocine, Inc.	Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US8143386B2 (en) *	1999-04-07	2012-03-27	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2000060940A1 (en) *	1999-04-12	2000-10-19	Dow Agrosciences Llc	Aqueous dispersions of agricultural chemicals
US6309749B1 (en)	1999-05-06	2001-10-30	Eastman Kodak Company	Ceramic milling media containing tetragonal zirconia
US6491239B2 (en)	1999-05-06	2002-12-10	Eastman Kodak Company	Process for milling compounds
US6444223B1 (en) *	1999-05-28	2002-09-03	Alkermes Controlled Therapeutics, Inc.	Method of producing submicron particles of a labile agent and use thereof
JP4156807B2 (ja)	1999-06-01	2008-09-24	エランファーマインターナショナル，リミティド	小型ミル及びその方法
US20090104273A1 (en) *	1999-06-22	2009-04-23	Elan Pharma International Ltd.	Novel nifedipine compositions
US20040115134A1 (en) *	1999-06-22	2004-06-17	Elan Pharma International Ltd.	Novel nifedipine compositions
US6555139B2 (en)	1999-06-28	2003-04-29	Wockhardt Europe Limited	Preparation of micron-size pharmaceutical particles by microfluidization
AU779986B2 (en) *	1999-06-29	2005-02-24	Mannkind Corporation	Purification and stabilization of peptide and protein pharmaceutical agents
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
US6458383B2 (en)	1999-08-17	2002-10-01	Lipocine, Inc.	Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6982281B1 (en) *	2000-11-17	2006-01-03	Lipocine Inc	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en)	1999-08-17	2001-10-30	Lipocine Inc.	Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2001001962A1 (en) *	1999-07-05	2001-01-11	Idea Ag.	A method for the improvement of transport across adaptable semi-permeable barriers
US6576224B1 (en) *	1999-07-06	2003-06-10	Sinuspharma, Inc.	Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
FR2795961B1 (fr) *	1999-07-09	2004-05-28	Ethypharm Lab Prod Ethiques	Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en)	1999-07-09	2011-01-04	Ethypharm	Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US6933318B1 (en)	1999-08-12	2005-08-23	Eli Lilly And Company	Topical organic ectoparasiticidal formulations
US6927210B1 (en)	1999-08-12	2005-08-09	Eli Lilly And Company	Ectoparasiticidal aqueous suspension formulations of spinosyns
DE122011100022I1 (de)	1999-08-12	2011-10-20	Lilly Co Eli	Verwendung von Spinosad oder einer Zusammensetzungenthaltend spinosad.
US6749835B1 (en)	1999-08-25	2004-06-15	Advanced Inhalation Research, Inc.	Formulation for spray-drying large porous particles
US7678364B2 (en)	1999-08-25	2010-03-16	Alkermes, Inc.	Particles for inhalation having sustained release properties
US20010036481A1 (en) *	1999-08-25	2001-11-01	Advanced Inhalation Research, Inc.	Modulation of release from dry powder formulations
WO2001013891A2 (en) *	1999-08-25	2001-03-01	Advanced Inhalation Research, Inc.	Modulation of release from dry powder formulations
US6656504B1 (en)	1999-09-09	2003-12-02	Elan Pharma International Ltd.	Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
EP1229931A4 (en) *	1999-10-07	2003-05-28	Corixa Corp	FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
KR20130010512A (ko)	1999-10-29	2013-01-28	유로-셀티크 소시에떼 아노뉨	서방성 하이드로코돈 제형
US20030096798A1 (en) *	1999-11-09	2003-05-22	Williams Gordon H.	Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030203884A1 (en) *	1999-11-09	2003-10-30	Pharmacia Corporation	Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
AUPQ441699A0 (en)	1999-12-02	2000-01-06	Eli Lilly And Company	Pour-on formulations
UA74539C2 (en)	1999-12-08	2006-01-16	Pharmacia Corp	Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
US20030083493A1 (en) *	1999-12-08	2003-05-01	Barton Kathleen P.	Eplerenone drug substance having high phase purity
US6251136B1 (en)	1999-12-08	2001-06-26	Advanced Cardiovascular Systems, Inc.	Method of layering a three-coated stent using pharmacological and polymeric agents
US7172769B2 (en) *	1999-12-08	2007-02-06	Pharmacia Corporation	Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
IL144757A0 (en) *	1999-12-08	2002-06-30	Pharmacia Corp	Eplerenone crystalline form
US6702849B1 (en)	1999-12-13	2004-03-09	Advanced Cardiovascular Systems, Inc.	Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
US8771740B2 (en) *	1999-12-20	2014-07-08	Nicholas J. Kerkhof	Process for producing nanoparticles by spray drying
AU2583401A (en)	1999-12-20	2001-07-03	Cocensys, Inc.	Process for producing nanometer particles by fluid bed spray-drying
YU43702A (sh)	1999-12-23	2004-11-25	Pfizer Products Inc.	Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
GB9930562D0 (en) *	1999-12-23	2000-02-16	Boc Group Plc	Partial oxidation of hydrogen sulphide
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
JP2004501068A (ja) *	2000-01-31	2004-01-15	コラボレイティヴ・テクノロジーズ・インコーポレーテッド	界面活性剤を含まない局所用組成物、及びその迅速な調製方法
PT1265915E (pt)	2000-02-23	2011-02-07	Glaxosmithkline Biolog Sa	Novos compostos
AU2001241738A1 (en) *	2000-02-25	2001-09-03	Corixa Corporation	Compounds and methods for diagnosis and immunotherapy of tuberculosis
EP1267946A4 (en) *	2000-02-28	2008-07-02	Genesegues Inc	SYSTEM AND METHOD FOR ENCAPSULATING NANOCAPSULES
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AUPQ634300A0 (en) *	2000-03-20	2000-04-15	Eli Lilly And Company	Synergistic formulations
US7153525B1 (en) *	2000-03-22	2006-12-26	The University Of Kentucky Research Foundation	Microemulsions as precursors to solid nanoparticles
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
CA2401749A1 (en) *	2000-03-23	2001-09-27	Elan Pharmaceuticals, Inc.	Compounds and methods to treat alzheimer's disease
GB0009773D0 (en) *	2000-04-19	2000-06-07	Univ Cardiff	Particulate composition
JP5102423B2 (ja)	2000-04-20	2012-12-19	オバン・エナジー・リミテッド	改善された水不溶性薬剤粒子の処理
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1280520B2 (en)	2000-05-10	2018-03-21	Novartis AG	Phospholipid-based powders for drug delivery
EP1280604B1 (en)	2000-05-10	2008-03-19	Jagotec AG	Media milling
US8404217B2 (en)	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6316029B1 (en) *	2000-05-18	2001-11-13	Flak Pharma International, Ltd.	Rapidly disintegrating solid oral dosage form
US20040156872A1 (en) *	2000-05-18	2004-08-12	Elan Pharma International Ltd.	Novel nimesulide compositions
MY120279A (en) *	2000-05-26	2005-09-30	Pharmacia Corp	Use of a celecoxib composition for fast pain relief
DK1542732T3 (da)	2000-06-20	2009-12-14	Corixa Corp	Fusionsproteiner af Mycobacterium tuberculosis
AU2001270183A1 (en) *	2000-06-27	2002-01-08	Genelabs Technologies, Inc.	Novel compounds possessing antibacterial, antifungal or antitumor activity
AU2001273149A1 (en)	2000-06-28	2002-01-08	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
US6846813B2 (en) *	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
DE60116313T2 (de)	2000-06-30	2006-08-31	Elan Pharmaceuticals, Inc., San Francisco	Verbindungen zur behandlung der alzheimerischen krankheit
EP1666452A2 (en)	2000-06-30	2006-06-07	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030096864A1 (en) *	2000-06-30	2003-05-22	Fang Lawrence Y.	Compounds to treat alzheimer's disease
IN192160B (zh) *	2000-07-17	2004-02-28	Ranbaxy Lab
US6656505B2 (en) *	2000-07-21	2003-12-02	Alpharma Uspd Inc.	Method for forming an aqueous flocculated suspension
DK1303306T3 (da) *	2000-07-27	2006-10-23	Pharmacia Corp	Epoxysteroidaldosteronantagonist og beta-adrenerg antagonist-kombinationsterapi til behandling af kongestivt hjertesvigt
US6716829B2 (en)	2000-07-27	2004-04-06	Pharmacia Corporation	Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
DE60114027T2 (de) *	2000-08-28	2006-07-13	Pharmacia Corp.	Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion
WO2002017883A2 (en)	2000-08-31	2002-03-07	Rtp Pharma Inc.	Milled particles
US8586094B2 (en)	2000-09-20	2013-11-19	Jagotec Ag	Coated tablets
US20030224058A1 (en) *	2002-05-24	2003-12-04	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
US7998507B2 (en) *	2000-09-21	2011-08-16	Elan Pharma International Ltd.	Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7198795B2 (en) *	2000-09-21	2007-04-03	Elan Pharma International Ltd.	In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) *	2002-05-24	2007-10-02	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
US20080241070A1 (en) *	2000-09-21	2008-10-02	Elan Pharma International Ltd.	Fenofibrate dosage forms
CN101317825A (zh)	2000-10-30	2008-12-10	欧罗赛铁克股份有限公司	控释氢可酮制剂
US8551526B2 (en) *	2000-11-03	2013-10-08	Board Of Regents, The University Of Texas System	Preparation of drug particles using evaporation precipitation into aqueous solutions
US6756062B2 (en)	2000-11-03	2004-06-29	Board Of Regents University Of Texas System	Preparation of drug particles using evaporation precipitation into aqueous solutions
US20030198679A1 (en) *	2000-11-08	2003-10-23	Kundu Subhas C.	Flocculated pharmaceutical suspensions and methods for actives
DE60136490D1 (de) *	2000-11-09	2008-12-18	Neopharm Inc	Sn-38-lipidkomplexe und verfahren zu ihrer verwendung
GB0028583D0 (en) *	2000-11-23	2001-01-10	Merck Sharp & Dohme	Therapeutic compounds
ATE446085T1 (de)	2000-11-30	2009-11-15	Vectura Ltd	Partikel zur verwendung in einer pharmazeutischen zusammensetzung
PT2283818T (pt)	2000-11-30	2017-10-09	Vectura Ltd	Método de preparação de partículas para utilização numa composição farmacêutica
WO2002045691A2 (en) *	2000-12-06	2002-06-13	Pharmacia Corporation	Laboratory scale milling process
PL362172A1 (en) *	2000-12-11	2004-10-18	Takeda Chemical Industries, Ltd.	Medicinal compositions having improved absorbability
DE10063092A1 (de) *	2000-12-18	2002-06-20	Henkel Kgaa	Nanoskalige Materialien in Hygiene-Produkten
DE10063090A1 (de) *	2000-12-18	2002-06-20	Henkel Kgaa	Nanoskaliges ZnO in Hygiene-Produkten
US6982251B2 (en) *	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030072807A1 (en) *	2000-12-22	2003-04-17	Wong Joseph Chung-Tak	Solid particulate antifungal compositions for pharmaceutical use
US20030096013A1 (en) *	2000-12-22	2003-05-22	Jane Werling	Preparation of submicron sized particles with polymorph control
US7193084B2 (en) *	2000-12-22	2007-03-20	Baxter International Inc.	Polymorphic form of itraconazole
MXPA03005496A (es) *	2000-12-22	2004-05-14	Baxter Int	Metodo para preparar suspensiones de submicroparticulas.
US20040022862A1 (en) *	2000-12-22	2004-02-05	Kipp James E.	Method for preparing small particles
US6623761B2 (en)	2000-12-22	2003-09-23	Hassan Emadeldin M.	Method of making nanoparticles of substantially water insoluble materials
US6951656B2 (en) *	2000-12-22	2005-10-04	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) *	2000-12-22	2005-12-20	Baxter International Inc.	Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) *	2000-12-22	2011-11-29	Baxter International Inc.	Method for preparing submicron particles of antineoplastic agents
US20050048126A1 (en)	2000-12-22	2005-03-03	Barrett Rabinow	Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6869617B2 (en) *	2000-12-22	2005-03-22	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) *	2000-12-22	2005-04-26	Baxter International Inc.	Method for preparing submicron particle suspensions
US9700866B2 (en)	2000-12-22	2017-07-11	Baxter International Inc.	Surfactant systems for delivery of organic compounds
RU2272616C2 (ru) *	2000-12-22	2006-03-27	Бакстер Интернэшнл Инк.	Способ получения суспензий субмикронных частиц
WO2002062755A2 (en) *	2000-12-27	2002-08-15	Genelabs Technologies, Inc.	Polyamide analogs as dna minor groove binders
US20020141946A1 (en) *	2000-12-29	2002-10-03	Advanced Inhalation Research, Inc.	Particles for inhalation having rapid release properties
WO2002053190A2 (en)	2000-12-29	2002-07-11	Advanced Inhalation Research, Inc.	Particles for inhalation having sustained release properties
US20030125236A1 (en) *	2000-12-29	2003-07-03	Advenced Inhalation Research, Inc.	Particles for inhalation having rapid release properties
FI20010115A0 (fi) *	2001-01-18	2001-01-18	Orion Corp	Menetelmä nanopartikkelien valmistamiseksi
PL205343B1 (pl) *	2001-01-26	2010-04-30	Schering Corp	Zastosowanie inhibitora wchłaniania sterolu
MXPA03006631A (es) *	2001-01-26	2004-03-18	Schering Corp	Combinaciones de secuestrante(s) de los acidos biliares y de inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
BR0206639A (pt) *	2001-01-26	2004-02-25	Schering Corp	Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
SI1413331T1 (sl) *	2001-01-26	2008-02-29	Schering Corp	Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
AU2002240050A1 (en) *	2001-01-26	2002-08-06	Schering Corporation	Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) *	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
KR20040025889A (ko) *	2001-01-26	2004-03-26	쉐링 코포레이션	혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와심혈관성 제제의 조합물
US20040022861A1 (en) *	2001-01-30	2004-02-05	Williams Robert O.	Process for production of nanoparticles and microparticles by spray freezing into liquid
US6862890B2 (en) *	2001-01-30	2005-03-08	Board Of Regents, University Of Texas System	Process for production of nanoparticles and microparticles by spray freezing into liquid
US6497896B2 (en)	2001-02-12	2002-12-24	Supergen, Inc.	Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
US6509027B2 (en)	2001-02-12	2003-01-21	Supergen, Inc.	Injectable pharmaceutical composition comprising coated particles of camptothecin
US20020150615A1 (en) *	2001-02-12	2002-10-17	Howard Sands	Injectable pharmaceutical composition comprising microdroplets of a camptothecin
JP3386052B2 (ja) *	2001-02-13	2003-03-10	トヨタ自動車株式会社	ポンプ装置
CN101230067B (zh)	2001-02-14	2011-06-15	泰博特克药品有限公司	广谱的2-(取代-氨基)-苯并噻唑磺酰胺hiv蛋白酶抑制剂
US6534088B2 (en) *	2001-02-22	2003-03-18	Skyepharma Canada Inc.	Fibrate-statin combinations with reduced fed-fasted effects
DE10114244A1 (de) *	2001-03-22	2002-10-02	Heraeus Kulzer Gmbh & Co Kg	Antibiotikum-/Antibiotika-Zubereitung mit retardierender Wirkstofffreisetzung
EP2090165A3 (en) *	2001-04-03	2012-03-28	Schering Corporation	Antifungal composition with enhanced bioavailability
EP1392245A2 (en) *	2001-04-05	2004-03-03	Universite Laval	Process for making protein delivery matrix and uses thereof
JP4417010B2 (ja)	2001-04-09	2010-02-17	テイボテク・フアーマシユーチカルズ・リミテツド	広範囲２−（置換−アミノ）−ベンズオキサゾールスルホンアミドｈｉｖプロテアーゼ阻害剤
US20040126900A1 (en) *	2001-04-13	2004-07-01	Barry Stephen E	High affinity peptide- containing nanoparticles
US6667344B2 (en)	2001-04-17	2003-12-23	Dey, L.P.	Bronchodilating compositions and methods
CA2445763A1 (en) *	2001-05-01	2002-11-07	Angiotech Pharmaceuticals Inc.	Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
US20030157161A1 (en) *	2001-05-01	2003-08-21	Angiotech Pharmaceuticals, Inc.	Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
ITMO20010086A1 (it) *	2001-05-08	2002-11-08	Worgas Bruciatori Srl	Metodo ed apparato per ridurre le emissioni di biossido di azoto (no2)in un apparecchio da riscaldamento senza canna fumaria
JP2005504513A (ja)	2001-05-09	2005-02-17	コリクサコーポレイション	前立腺癌の治療及び診断のための組成物及び方法
CN100549007C (zh)	2001-05-11	2009-10-14	泰博特克药品有限公司	广谱2-氨基-苯并唑磺酰胺hiv蛋白酶抑制剂
DE10125290B4 (de) *	2001-05-15	2005-04-14	Siemens Ag	Verfahren zum Aufbereiten von Nano-Dispersanten
EP1392440A2 (en) *	2001-05-23	2004-03-03	E.I. Du Pont De Nemours And Company	High pressure media mill
DE60216275T2 (de) *	2001-05-25	2007-06-21	Schering Corp.	Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
WO2003030864A1 (en) *	2001-05-29	2003-04-17	Neopharm, Inc.	Liposomal formulation of irinotecan
DE60227802D1 (de) *	2001-06-05	2008-09-04	Elan Pharma Int Ltd	Mahlvorrichtung und verfahren zu deren betrieb
US6976647B2 (en) *	2001-06-05	2005-12-20	Elan Pharma International, Limited	System and method for milling materials
US6730319B2 (en)	2001-06-06	2004-05-04	Hoffmann-La Roche Inc.	Pharmaceutical compositions having depressed melting points
US20040173146A1 (en) *	2001-06-07	2004-09-09	Figueroa Iddys D.	Application of a bioactive agent to a delivery substrate
US20040173147A1 (en) *	2001-06-07	2004-09-09	Figueroa Iddys D.	Application of a bioactive agent to a delivery substrate
US6962715B2 (en) *	2001-10-24	2005-11-08	Hewlett-Packard Development Company, L.P.	Method and dosage form for dispensing a bioactive substance
MXPA03011521A (es)	2001-06-13	2004-03-18	Elan Pharm Inc	Aminadioles para tratamiento de enfermedad de alzheimer.
GB0114532D0 (en) *	2001-06-14	2001-08-08	Jagotec Ag	Novel compositions
AU2002309172A1 (en) *	2001-06-22	2003-01-08	Pfizer Products Inc.	Pharmaceutical compositions containing polymer and drug assemblies
DE60203506T2 (de) *	2001-06-22	2006-02-16	Marie Lindner	Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
EP1269994A3 (en) *	2001-06-22	2003-02-12	Pfizer Products Inc.	Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US7758890B2 (en) *	2001-06-23	2010-07-20	Lyotropic Therapeutics, Inc.	Treatment using dantrolene
EP1401452A1 (en) *	2001-06-27	2004-03-31	Elan Pharmaceuticals, Inc.	Beta-hydroxyamine derivatives useful in the treatment of alzheimer's disease
JP2005504022A (ja) *	2001-07-10	2005-02-10	イーランファーマスーティカルズ、インコーポレイテッド	アルツハイマー病治療のためのジアミンジオール
JP2005505517A (ja) *	2001-07-10	2005-02-24	イーランファーマスーティカルズ、インコーポレイテッド	アルツハイマー病を治療するためのアミンジオール
GB0208742D0 (en)	2002-04-17	2002-05-29	Bradford Particle Design Ltd	Particulate materials
US20030220310A1 (en) *	2001-07-27	2003-11-27	Schuh Joseph R.	Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20080305173A1 (en) *	2001-07-31	2008-12-11	Beuford Arlie Bogue	Amorphous drug beads
IL160103A0 (en) *	2001-08-06	2004-06-20	Astrazeneca Ab	Aqueous dispersion comprising stable nanoparticles of a water-insoluble active substance and an excipient like middle chain triglycerides (mct)
GB0119480D0 (en) *	2001-08-09	2001-10-03	Jagotec Ag	Novel compositions
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
ATE336231T1 (de) *	2001-08-29	2006-09-15	Dow Global Technologies Inc	Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung
US20030054042A1 (en) *	2001-09-14	2003-03-20	Elaine Liversidge	Stabilization of chemical compounds using nanoparticulate formulations
ES2365993T5 (es) *	2001-09-17	2020-06-25	Elanco Us Inc	Formulaciones pesticidas
US20030095928A1 (en) *	2001-09-19	2003-05-22	Elan Pharma International Limited	Nanoparticulate insulin
US7056906B2 (en) *	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
MXPA04002573A (es) *	2001-09-21	2004-06-18	Schering Corp	Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
CN1556700A (zh) *	2001-09-21	2004-12-22	��鹫˾	使用甾醇吸收抑制剂治疗或预防脉管炎的方法
US20030119808A1 (en) *	2001-09-21	2003-06-26	Schering Corporation	Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) *	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005529060A (ja) *	2001-09-25	2005-09-29	ファルマシアコーポレイション	Ｎ−（２−ヒドロキシアセチル）−５−（４−ピペリヂル）−４−（４−ピリミヂニル）−３−（４−クロロフェニル）ピラゾールの固体形態
US20060003012A9 (en) *	2001-09-26	2006-01-05	Sean Brynjelsen	Preparation of submicron solid particle suspensions by sonication of multiphase systems
AU2002337692B2 (en)	2001-09-26	2007-09-13	Baxter International Inc.	Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7544681B2 (en) *	2001-09-27	2009-06-09	Ramot At Tel Aviv University Ltd.	Conjugated psychotropic drugs and uses thereof
US20050233003A1 (en) *	2001-09-28	2005-10-20	Solubest Ltd.	Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US20050191359A1 (en) *	2001-09-28	2005-09-01	Solubest Ltd.	Water soluble nanoparticles and method for their production
US20050227911A1 (en) *	2001-09-28	2005-10-13	Solubest Ltd.	Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US6878693B2 (en) *	2001-09-28	2005-04-12	Solubest Ltd.	Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
MXPA04003245A (es)	2001-10-04	2004-08-11	Elan Pharm Inc	Hidroxipropilaminas.
PT1443912E (pt) *	2001-10-12	2007-11-28	Elan Pharma Int Ltd	Composições tendo uma combinação de características de libertação imediata e de libertação controlada
CA2461556A1 (en) *	2001-10-15	2003-04-24	Crititech, Inc.	Compositions and methods for delivery of microparticles of poorly water soluble drugs and methods of treatment
US7112340B2 (en) *	2001-10-19	2006-09-26	Baxter International Inc.	Compositions of and method for preparing stable particles in a frozen aqueous matrix
TWI330183B (zh) *	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
EP1450863A4 (en) *	2001-11-07	2009-01-07	Imcor Pharmaceutical Company	PROCESS FOR IMAGING VESSELS WITH NANOTEHTIC CONTAINERS
US7176242B2 (en) *	2001-11-08	2007-02-13	Elan Pharmaceuticals, Inc.	N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives
US7700851B2 (en) *	2001-11-13	2010-04-20	U.S. Smokeless Tobacco Company	Tobacco nicotine demethylase genomic clone and uses thereof
WO2003043618A2 (en) *	2001-11-19	2003-05-30	Elan Pharmaceuticals, Inc.	Amino diols useful in the treatment of alzheimer's disease
GB0127805D0 (en) *	2001-11-20	2002-01-09	Smithkline Beecham Plc	Pharmaceutical composition
US7182961B2 (en) *	2001-11-20	2007-02-27	Advanced Inhalation Research, Inc.	Particulate compositions for pulmonary delivery
WO2003043603A1 (en) *	2001-11-20	2003-05-30	Advanced Inhalation Research, Inc.	Particulate compositions for improving solubility of poorly soluble agents
UA76810C2 (uk) *	2001-12-10	2006-09-15	Мерк Енд Ко., Інк.	Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
ES2405405T3 (es)	2001-12-17	2013-05-31	Corixa Corporation	Composiciones y procedimientos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
ES2364636T3 (es)	2001-12-19	2011-09-08	Novartis Ag	Administración pulmonar de aminoglucósidos.
PL370889A1 (en) *	2001-12-20	2005-05-30	Femmepharma, Inc.	Vaginal delivery of drugs
US20030235619A1 (en) *	2001-12-21	2003-12-25	Christine Allen	Polymer-lipid delivery vehicles
AU2002351626A1 (en) *	2001-12-21	2003-07-15	Celator Technologies Inc.	Improved polymer-lipid delivery vehicles
EA009556B1 (ru)	2001-12-21	2008-02-28	Тиботек Фармасьютикалз Лтд.	Гетероциклические замещённые фенилсодержащие сульфонамиды широкого спектра действия в качестве ингибиторов протеазы вич
AU2002364209A1 (en) *	2001-12-26	2003-07-24	Genelabs Technologies, Inc.	Polyamide derivatives possessing antibacterial, antifungal or antitumor activity
US20030129242A1 (en) *	2002-01-04	2003-07-10	Bosch H. William	Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
EP1467709A1 (en) *	2002-01-14	2004-10-20	Dow Global Technologies Inc.	Drug nanoparticles from template emulsions
JP4547911B2 (ja)	2002-02-01	2010-09-22	アリアド・ファーマシューティカルズ・インコーポレイテッド	リン含有化合物およびその用途
PL371416A1 (en) *	2002-02-01	2005-06-13	Pfizer Products Inc.	Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
ATE464880T1 (de)	2002-02-04	2010-05-15	Elan Pharma Int Ltd	Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
US7026465B2 (en)	2002-02-15	2006-04-11	Corixa Corporation	Fusion proteins of Mycobacterium tuberculosis
MY142238A (en)	2002-03-12	2010-11-15	Tibotec Pharm Ltd	Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
GB0206200D0 (en) *	2002-03-15	2002-05-01	Glaxo Group Ltd	Pharmaceutical compositions
ES2425392T3 (es)	2002-03-20	2013-10-15	Mannkind Corporation	Cartucho para un aparato de inhalación
EP1490030B2 (en) *	2002-03-20	2010-07-14	Elan Pharma International Limited	Nanoparticulate compositions of angiogenesis inhibitors
AU2003230692A1 (en) *	2002-03-20	2003-10-08	Elan Pharma International Ltd.	Nanoparticulate compositions of map kinase inhibitors
US20080220075A1 (en) *	2002-03-20	2008-09-11	Elan Pharma International Ltd.	Nanoparticulate compositions of angiogenesis inhibitors
CA2479735C (en) *	2002-03-20	2011-05-17	Elan Pharma International Ltd.	Fast dissolving dosage forms having reduced friability
EP1800666A1 (en) *	2002-03-20	2007-06-27	Elan Pharma International Limited	Nanoparticulate compositions of angiogenesis inhibitors
US20040076586A1 (en) *	2002-03-28	2004-04-22	Reinhard Koening	Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
US7799523B2 (en)	2002-04-03	2010-09-21	Celltech R & D, Inc.	Association of polymorphisms in the SOST gene region with bone mineral density
US20040038303A1 (en) *	2002-04-08	2004-02-26	Unger Gretchen M.	Biologic modulations with nanoparticles
US7101576B2 (en) *	2002-04-12	2006-09-05	Elan Pharma International Limited	Nanoparticulate megestrol formulations
EP1494649B1 (en) *	2002-04-12	2012-01-04	Alkermes Pharma Ireland Limited	Nanoparticulate megestrol formulations
US20100226989A1 (en) *	2002-04-12	2010-09-09	Elan Pharma International, Limited	Nanoparticulate megestrol formulations
US9101540B2 (en) *	2002-04-12	2015-08-11	Alkermes Pharma Ireland Limited	Nanoparticulate megestrol formulations
US20040105889A1 (en) *	2002-12-03	2004-06-03	Elan Pharma International Limited	Low viscosity liquid dosage forms
US7582284B2 (en)	2002-04-17	2009-09-01	Nektar Therapeutics	Particulate materials
DE10218109A1 (de)	2002-04-23	2003-11-20	Jenapharm Gmbh	Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
US8501232B2 (en) *	2002-04-23	2013-08-06	Nanotherapeutics, Inc.	Process of forming and modifying particles and compositions produced thereby
WO2004058686A1 (en) *	2002-04-30	2004-07-15	Elan Pharmaceuticals, Inc.	Hydroxypropyl amides for the treatment of alzheimer’s disease
WO2003094894A1 (en) *	2002-05-06	2003-11-20	Elan Pharma International Ltd.	Nanoparticulate nystatin formulations
TWI356700B (en)	2002-05-17	2012-01-21	Tibotec Pharm Ltd	Broadspectrum substituted benzisoxazole sulfonamid
US20070264348A1 (en) *	2002-05-24	2007-11-15	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
US8313760B2 (en)	2002-05-24	2012-11-20	Angiotech International Ag	Compositions and methods for coating medical implants
AU2003234670B2 (en) *	2002-05-24	2010-06-10	Angiotech International Ag	Compositions and methods for coating medical implants
AU2003241477A1 (en) *	2002-06-10	2003-12-22	Elan Pharma International, Ltd.	Nanoparticulate polycosanol formulations and novel polycosanol combinations
JP4831965B2 (ja) *	2002-06-10	2011-12-07	エランファーマインターナショナル，リミティド	ＨＭＧ−ＣｏＡ還元酵素インヒビター誘導体（「スタチン」）を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造
EP2283864A1 (en)	2002-07-16	2011-02-16	Elan Pharma International Ltd.	Liquid dosage compositions fo stable nanoparticulate active agents
GB0216700D0 (en) *	2002-07-18	2002-08-28	Astrazeneca Ab	Process
US20030017208A1 (en) *	2002-07-19	2003-01-23	Francis Ignatious	Electrospun pharmaceutical compositions
AR040588A1 (es) *	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2002950426A0 (en) *	2002-07-29	2002-09-12	Patrick John Shanahan	Anti microbial oro-dental system
DE10234784A1 (de) *	2002-07-30	2004-02-19	Günenthal GmbH	Intravenös applizierbare, pharmazeutische Darreichungsform
US7838034B2 (en)	2002-07-30	2010-11-23	Grunenthal Gmbh	Intravenous pharmaceutical form of administration
US20040023935A1 (en) *	2002-08-02	2004-02-05	Dey, L.P.	Inhalation compositions, methods of use thereof, and process for preparation of same
US20040028746A1 (en) *	2002-08-06	2004-02-12	Sonke Svenson	Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
US20040028747A1 (en) *	2002-08-06	2004-02-12	Tucker Christopher J.	Crystalline drug particles prepared using a controlled precipitation process
DE60329188D1 (de)	2002-08-12	2009-10-22	Bend Res Inc	Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
AP2126A (en)	2002-08-14	2010-06-03	Tibotec Pharm Ltd	Broadspectrum substituted oxindole sulfonamide HIVprotease inhibitors
US7445796B2 (en) *	2002-08-19	2008-11-04	L. Perrigo Company	Pharmaceutically active particles of a monomodal particle size distribution and method
US20060030578A1 (en) *	2002-08-20	2006-02-09	Neopharm, Inc.	Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (en) *	2002-08-20	2004-04-29	Neopharm, Inc.	Pharmaceutical formulations of camptothecine derivatives
UY27939A1 (es)	2002-08-21	2004-03-31	Glaxo Group Ltd	Compuestos
WO2004019873A2 (en) *	2002-08-29	2004-03-11	Scios Inc.	Methods of promoting osteogenesis
WO2004019937A1 (en) *	2002-09-02	2004-03-11	Sun Pharmaceutical Industries Limited	Pharmaceutical composition of metaxalone with enhanced oral bioavailability
EP1553927B9 (en)	2002-09-11	2011-09-21	Elan Pharma International Limited	Gel-stabilized nanoparticulate active agent compositions
WO2004053056A2 (en) *	2002-09-24	2004-06-24	University Of Kentucky Research Foundation	Nanoparticle-based vaccine delivery system containing adjuvant
US20040105778A1 (en) *	2002-10-04	2004-06-03	Elan Pharma International Limited	Gamma irradiation of solid nanoparticulate active agents
US7473432B2 (en)	2002-10-11	2009-01-06	Idea Ag	NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
EP1562555A2 (en) *	2002-10-24	2005-08-17	Enos Pharmaceuticals, Inc.	Sustained release l-arginine formulations and methods of manufacture and use
US20080145424A1 (en) *	2002-10-24	2008-06-19	Enos Phramaceuticals, Inc.	Sustained release L-arginine formulations and methods of manufacture and use
MXPA05004811A (es) *	2002-11-06	2005-07-22	Schering Corp	Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
WO2004043440A1 (en) *	2002-11-12	2004-05-27	Elan Pharma International Ltd.	Fast-disintegrating solid dosage forms being not friable and comprising pullulan
GB0227443D0 (en) *	2002-11-25	2002-12-31	Glaxo Group Ltd	Pyrimidine derivatives
AU2003293155A1 (en) *	2002-11-27	2004-06-23	Elan Pharmaceutical, Inc.	Substituted ureas and carbamates
EP2982668A3 (en)	2002-12-03	2016-04-13	Pharmacyclics LLC	2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders
US20050095267A1 (en) *	2002-12-04	2005-05-05	Todd Campbell	Nanoparticle-based controlled release polymer coatings for medical implants
JP2006510654A (ja) *	2002-12-06	2006-03-30	サイオス・インコーポレーテツド	糖尿病を処置する方法
US20040109826A1 (en) *	2002-12-06	2004-06-10	Dey, L.P.	Stabilized albuterol compositions and method of preparation thereof
JP2006511525A (ja) *	2002-12-13	2006-04-06	ヤゴテックアーゲー	ナノ粒子状スピロノラクトン局所製剤
WO2004058216A2 (en) *	2002-12-17	2004-07-15	Elan Pharma International Ltd.	Milling microgram quantities of nanoparticulate candidate compounds
EP2474632B1 (en)	2002-12-20	2015-08-12	Celera Corporation	Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
GB0230088D0 (en) *	2002-12-24	2003-01-29	Astrazeneca Ab	Therapeutic agents
GB0230087D0 (en) *	2002-12-24	2003-01-29	Astrazeneca Ab	Therapeutic agents
US9173836B2 (en)	2003-01-02	2015-11-03	FemmeParma Holding Company, Inc.	Pharmaceutical preparations for treatments of diseases and disorders of the breast
US7812010B2 (en) *	2003-01-02	2010-10-12	Femmepharma, Inc.	Pharmaceutical preparations for treatments of diseases and disorders of the breast
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
CN101863930A (zh)	2003-01-06	2010-10-20	科里克萨有限公司	一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
WO2004078162A1 (en) *	2003-01-31	2004-09-16	Elan Pharma International Ltd.	Nanoparticulate topiramate formulations
US20040208833A1 (en) *	2003-02-04	2004-10-21	Elan Pharma International Ltd.	Novel fluticasone formulations
GB0302672D0 (en) *	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
GB0302673D0 (en) *	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
GB0302671D0 (en) *	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
US20100297252A1 (en)	2003-03-03	2010-11-25	Elan Pharma International Ltd.	Nanoparticulate meloxicam formulations
US8512727B2 (en)	2003-03-03	2013-08-20	Alkermes Pharma Ireland Limited	Nanoparticulate meloxicam formulations
US7235543B2 (en)	2003-03-07	2007-06-26	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004018617D1 (de)	2003-03-07	2009-02-05	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081004A1 (en)	2003-03-07	2004-09-23	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US20040184995A1 (en) *	2003-03-17	2004-09-23	Yamanouchi Pharmaceutical Co., Ltd.	Novel dry powder inhalation for lung-delivery and manufacturing method thereof
JP2006521366A (ja) *	2003-03-28	2006-09-21	シグモイド・バイオテクノロジーズ・リミテッド	シームレスマイクロカプセルを含む固形経口剤形
WO2004091875A2 (en) *	2003-04-09	2004-10-28	Osmose, Inc.	Micronized wood preservative formulations
US8747908B2 (en)	2003-04-09	2014-06-10	Osmose, Inc.	Micronized wood preservative formulations
US8637089B2 (en)	2003-04-09	2014-01-28	Osmose, Inc.	Micronized wood preservative formulations
UY28279A1 (es) *	2003-04-21	2004-11-30	Pharmacia & Amp	Fenacilo 2 -hidroxi - 3 - diaminoalcanos
WO2004094384A2 (en) *	2003-04-21	2004-11-04	Elan Pharmaceuticals, Inc.	(hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer’s disease
KR20060012628A (ko) *	2003-05-19	2006-02-08	백스터 인터내셔널 인코포레이티드	하나 이상의 표면 변형제로 피복시킨 항경련제 또는면역억제제를 포함하는 고형 입자
WO2004103345A2 (fr) *	2003-05-20	2004-12-02	L'oreal	Particules stabilisees en taille par copolymere diacide
FR2855051B1 (fr) *	2003-05-20	2006-08-25	Oreal	Particules stabilisees en taille par copolymere diacide
WO2004105809A1 (en) *	2003-05-22	2004-12-09	Elan Pharma International Ltd.	Sterilization of dispersions of nanoparticulate active agents with gamma radiation
EP1631261B1 (en) *	2003-05-22	2009-07-15	Applied NanoSystems B.V.	Production of small particles
US7459146B2 (en) *	2003-05-30	2008-12-02	3M Innovative Properties Company	Stabilized aerosol dispersions
US7109247B2 (en)	2003-05-30	2006-09-19	3M Innovative Properties Company	Stabilized particle dispersions containing nanoparticles
DE10325989A1 (de) *	2003-06-07	2005-01-05	Glatt Gmbh	Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
MEP2808A (xx) *	2003-06-16	2010-02-10	Celltech R & D Inc	Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju
JP4971790B2 (ja)	2003-06-17	2012-07-11	オズモウズ，インコーポレーテッド	微粒子状木材保存剤及びその製造方法
EP1641779A1 (en) *	2003-06-18	2006-04-05	AstraZeneca AB	2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
GB0314057D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
GB0314261D0 (en) *	2003-06-19	2003-07-23	Astrazeneca Ab	Therapeutic agents
BRPI0414970A2 (pt) *	2003-06-24	2012-12-11	Baxter Int	método para transporte de drogas ao cérebro
US8986736B2 (en) *	2003-06-24	2015-03-24	Baxter International Inc.	Method for delivering particulate drugs to tissues
TWI359675B (en)	2003-07-10	2012-03-11	Dey L P	Bronchodilating β-agonist compositions
US8308682B2 (en)	2003-07-18	2012-11-13	Broncus Medical Inc.	Devices for maintaining patency of surgically created channels in tissue
US20050042177A1 (en) *	2003-07-23	2005-02-24	Elan Pharma International Ltd.	Novel compositions of sildenafil free base
US20060151899A1 (en) *	2003-08-06	2006-07-13	Akira Kato	Process for producing drug ultramicroparticle and apparatus therefor
EP1651189B1 (en) *	2003-08-08	2008-12-03	Elan Pharma International Limited	Novel metaxalone compositions
US7419996B2 (en) *	2003-08-13	2008-09-02	The University Of Houston	Parenteral and oral formulations of benzimidazoles
GB0319797D0 (en) *	2003-08-26	2003-09-24	Leuven K U Res & Dev	Particle size reduction of poorly soluble drugs
KR20060115350A (ko) *	2003-09-02	2006-11-08	화이자 프로덕츠 인크.	지프라시돈의 지속 방출형 투여 형태
WO2005020933A2 (en) *	2003-09-02	2005-03-10	University Of South Florida	Nanoparticles for drug-delivery
ATE532509T1 (de)	2003-09-11	2011-11-15	Tibotec Pharm Ltd	Mittel zur hemmung des eintritts des hiv-virus
GB0327723D0 (en) *	2003-09-15	2003-12-31	Vectura Ltd	Pharmaceutical compositions
RU2392004C2 (ru)	2003-09-22	2010-06-20	Бакстер Интернэшнл Инк.	Стерилизация под высоким давлением для заключительной стерилизации фармацевтических препаратов и медицинских изделий
JP2007521324A (ja) *	2003-09-29	2007-08-02	エノスファーマシューティカルズ，インク．	徐放性ｌ−アルギニン調合物並びにその製造法及び使用法
US20060019971A1 (en) *	2003-09-30	2006-01-26	Higgins Linda S	Treatment of cardiovascular disease with inhibitors of p38 kinase
CA2542499A1 (en) *	2003-10-16	2005-04-28	Teva Pharmaceutical Industries Ltd.	Preparation of candesartan cilexetil
US7338171B2 (en) *	2003-10-27	2008-03-04	Jen-Chuen Hsieh	Method and apparatus for visual drive control
WO2005051356A1 (en) *	2003-10-31	2005-06-09	Elan Pharma International Ltd.	Novel nimesulide compositions
ATE509618T1 (de) *	2003-11-05	2011-06-15	Elan Pharma Int Ltd	Nanoteilchenförmige zusammensetzungen mit einem peptid als oberflächenstabilisator
JP2007510659A (ja) *	2003-11-05	2007-04-26	シェーリング　コーポレイション	脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
WO2005051871A2 (en) *	2003-11-20	2005-06-09	Angiotech International Ag	Implantable sensors and implantable pumps and anti-scarring agents
CZ300438B6 (cs) *	2003-11-25	2009-05-20	Pliva Hrvatska D.O.O.	Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
WO2005053851A1 (en) *	2003-11-26	2005-06-16	E.I. Dupont De Nemours And Company	High pressure media milling system and process of milling particles
CA2860272C (en)	2003-11-26	2017-12-19	Celera Corporation	Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
CN1878602A (zh) *	2003-11-28	2006-12-13	三菱化学株式会社	有机化合物微粒的制造方法
ES2562778T3 (es) *	2003-12-02	2016-03-08	The Ohio State University Research Foundation	Ácidos grasos de cadena corta unidos a motivos quelantes de Zn2+ como una clase novedosa de inhibidores de histona deacetilasa
KR100603974B1 (ko)	2003-12-05	2006-07-25	김갑식	고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법
WO2005067964A1 (en) *	2004-01-12	2005-07-28	Mannkind Corporation	A method of reducing serum proinsulin levels in type 2 diabetics
EP1729755A1 (en) *	2004-01-21	2006-12-13	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using aspartyl-protease inihibitors
WO2005072710A2 (en) *	2004-01-28	2005-08-11	Johns Hopkins University	Drugs and gene carrier particles that rapidly move through mucous barriers
CN1913871A (zh) *	2004-01-29	2007-02-14	巴克斯特国际公司	用于提高中枢神经系统投递的抗－逆转录病毒药剂的纳米悬浮液
US20050169978A1 (en) *	2004-01-29	2005-08-04	Shu-Wen Fu	Wet-micro grinding
EP1713795A2 (en) *	2004-02-11	2006-10-25	Teva Pharmaceutical Industries Ltd.	Candesartan cilexetil polymorphs
US20060014737A1 (en) *	2004-03-09	2006-01-19	Varghese John	Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
US20050239832A1 (en) *	2004-03-09	2005-10-27	Varghese John	Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
JP2007528404A (ja) *	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換された尿素およびカルバメート、フェナシル−２−ヒドロキシ−３−ジアミノアルカン、ならびにベンズアミド−２−ヒドロキシ−３−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
US20050239836A1 (en) *	2004-03-09	2005-10-27	Varghese John	Substituted hydroxyethylamine aspartyl protease inhibitors
JP2007528402A (ja) *	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
DE602004023765D1 (de) *	2004-03-12	2009-12-03	Trinity College Dublin	Magnetoresistives medium
US20080090753A1 (en)	2004-03-12	2008-04-17	Biodel, Inc.	Rapid Acting Injectable Insulin Compositions
US20050202051A1 (en) *	2004-03-15	2005-09-15	Chinea Vanessa I.	Pharmaceutical vehicle
US20050203482A1 (en) *	2004-03-15	2005-09-15	Chinea Vanessa I.	Pharmaceutical dispensing apparatus and method
ES2301003T3 (es) *	2004-03-30	2008-06-16	Smithkline Beecham Corporation	Composiciones farmaceuticas secadas por atomizacion.
DK1731138T3 (en) *	2004-03-31	2016-06-06	Toyama Chemical Co Ltd	Fine dispersion of sparingly soluble drug and the process for preparing the
AR048650A1 (es)	2004-05-04	2006-05-10	Tibotec Pharm Ltd	Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
CN1953973A (zh) *	2004-05-05	2007-04-25	特瓦制药工业有限公司	高纯度坎地沙坦酯的制备
JP5073480B2 (ja)	2004-05-07	2012-11-14	セコイア、ファーマシューティカルズ、インコーポレイテッド	耐性防止レトロウイルスプロテアーゼ阻害薬
CA2852855C (en)	2004-05-07	2016-07-05	Celera Corporation	Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
CA2564027A1 (en)	2004-05-17	2005-11-24	Tibotec Pharmaceuticals Ltd.	1-heterocyclyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones
WO2005111035A1 (en)	2004-05-17	2005-11-24	Tibotec Pharmaceuticals Ltd.	6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones useful as anti-infective pharmaceutical agents
AR052304A1 (es)	2004-05-17	2007-03-14	Tibotec Pharm Ltd	Compuestos 1,5- dihidro - pirido (3,2-b ) indol-2-onas4- sustituidos, composicion farmaceutica y proceso de preparacion del compuesto
US20050252408A1 (en)	2004-05-17	2005-11-17	Richardson H W	Particulate wood preservative and method for producing same
US7316738B2 (en)	2004-10-08	2008-01-08	Phibro-Tech, Inc.	Milled submicron chlorothalonil with narrow particle size distribution, and uses thereof
WO2006031264A2 (en)	2004-05-25	2006-03-23	Oregon Health And Science University	Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
WO2005115345A1 (en) *	2004-05-28	2005-12-08	Imaginot Pty Ltd	Oral therapeutic compound delivery system
US8216610B2 (en) *	2004-05-28	2012-07-10	Imaginot Pty Ltd.	Oral paracetamol formulations
US8445431B2 (en) *	2004-06-01	2013-05-21	The Ohio State University	Ligands having metal binding ability and targeting properties
US8012457B2 (en)	2004-06-04	2011-09-06	Acusphere, Inc.	Ultrasound contrast agent dosage formulation
MXPA06011171A (es) *	2004-06-15	2007-01-25	Baxter Int	Aplicacion ex-vivo de agentes terapeuticos microparticulados solidos.
WO2006002088A2 (en) *	2004-06-21	2006-01-05	The Ohio State University Research Foundation	Amino-quinazoline derivatives as antitumor agents
CA2572775A1 (en) *	2004-07-09	2006-01-26	Elan Pharmaceuticals, Inc.	Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
WO2006010095A2 (en) *	2004-07-09	2006-01-26	Elan Pharmaceuticals Inc.	Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
US8409167B2 (en)	2004-07-19	2013-04-02	Broncus Medical Inc	Devices for delivering substances through an extra-anatomic opening created in an airway
EP1786443B1 (en)	2004-07-19	2018-06-06	Celator Pharmaceuticals, Inc.	Particulate constructs for release of active agents
US8088756B2 (en) *	2004-08-18	2012-01-03	Concordia Pharmaceuticals, Inc.	Methods and compositions for oral delivery of FTS
US20060057206A1 (en) *	2004-08-19	2006-03-16	Wong Patrick S	Controlled release nanoparticle active agent formulation dosage forms and methods
DK1786784T3 (da)	2004-08-20	2011-02-14	Mannkind Corp	Katalyse af diketopiperazinsyntese
ES2543007T3 (es)	2004-08-23	2015-08-13	Mannkind Corporation	Micropartículas que comprenden sales de dicetopiperazina para la administración de fármacos
GB0418791D0 (en) *	2004-08-23	2004-09-22	Glaxo Group Ltd	Novel process
US9061027B2 (en) *	2004-08-27	2015-06-23	Board Of Regents, The University Of Texas System	Enhanced delivery of drug compositions to treat life threatening infections
EP1802574A2 (en) *	2004-08-27	2007-07-04	Elan Pharmaceuticals Inc.	Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
WO2006028074A1 (ja) *	2004-09-07	2006-03-16	Mitsubishi Chemical Corporation	微粒子化された物質の製造方法および微粒子化された物質
US20080171687A1 (en) *	2004-09-16	2008-07-17	Abraxis Bioscience, Inc.	Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
EP1811979B1 (en) *	2004-09-27	2008-11-05	Sigmoid Pharma Limited	Microcapsules comprising a methylxanthine and a corticosteroid
US7426948B2 (en) *	2004-10-08	2008-09-23	Phibrowood, Llc	Milled submicron organic biocides with narrow particle size distribution, and uses thereof
SI1799776T1 (sl) *	2004-10-14	2013-05-31	Osmose, Inc.	Mikronizirane formulacije za konzerviranje lesa v organskih nosilcih
KR100651728B1 (ko) *	2004-11-10	2006-12-06	한국전자통신연구원	정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
JP2008519784A (ja) *	2004-11-12	2008-06-12	イデアアクチェンゲゼルシャフト	皮膚状態の治療における拡張表面凝集体
US20090155331A1 (en) *	2005-11-16	2009-06-18	Elan Pharma International Limited	Injectable nanoparticulate olanzapine formulations
US7910577B2 (en) *	2004-11-16	2011-03-22	Elan Pharma International Limited	Injectable nanoparticulate olanzapine formulations
WO2006121468A1 (en) *	2004-11-22	2006-11-16	Genelabs Technologies, Inc.	5-nitro-nucleoside compounds for treating viral infections
UA89513C2 (uk) *	2004-12-03	2010-02-10	Элан Фарма Интернешнл Лтд.	Стабільна композиція з наночастинок ралоксифену гідрохлориду
JPWO2006062238A1 (ja) *	2004-12-07	2008-06-12	味の素株式会社	アミノ酸の微粉末及びその懸濁液
US20080145430A1 (en) *	2004-12-08	2008-06-19	Santipharp Panmai	Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
KR20070116581A (ko) *	2004-12-15	2007-12-10	엘란 파마 인터내셔널 리미티드	나노입자형 타크롤리무스 제제
EP1837015A1 (en) *	2004-12-17	2007-09-26	Mitsubishi Chemical Corporation	Novel core-shell structure
US20060159767A1 (en) *	2004-12-22	2006-07-20	Elan Pharma International Limited	Nanoparticulate bicalutamide formulations
JP6091041B2 (ja) *	2004-12-31	2017-03-08	イシューティカピーティーワイリミテッド	ナノ粒子組成物及びその合成方法
AU2005321751B2 (en) *	2004-12-31	2012-04-05	Iceutica Pty Ltd	Nanoparticle composition and methods for synthesis thereof
AU2012201630B8 (en) *	2004-12-31	2014-03-06	Iceutica Pty Ltd	NanoParticle Composition(s) and Method for Synthesis Thereof
JP2008526855A (ja) *	2005-01-06	2008-07-24	エランファーマインターナショナルリミテッド	ナノ粒子のカンデサルタン製剤
US20080145431A1 (en) *	2005-01-07	2008-06-19	Teruko Nomura	Medicinal Composition and Process for Producing the Same
US8623405B2 (en) *	2005-01-28	2014-01-07	Takeda Pharmaceutical Company Limited	Finely divided composition containing poorly water soluble substance
ES2265262B1 (es) *	2005-01-31	2008-03-01	Activery Biotech, S.L.(Titular Al 50%)	Procedimiento para la obtencion de sistemas micro- y nanodispersos.
WO2006086402A2 (en)	2005-02-08	2006-08-17	Research Development Foundation	Compositions and methods related to soluble g-protein coupled receptors(sgpcrs)
CN101189001A (zh) *	2005-02-15	2008-05-28	伊兰制药国际有限公司	纳米微粒苯并二氮杂䓬气雾剂及注射剂
CA2597685A1 (en) *	2005-02-28	2006-09-08	Genelabs Technologies, Inc.	Tricyclic-nucleoside compounds for treating viral infections
AU2005100176A4 (en) *	2005-03-01	2005-04-07	Gym Tv Pty Ltd	Garbage bin clip
CA2598288A1 (en) *	2005-03-03	2006-09-14	Elan Pharma International Limited	Nanoparticulate compositions of heterocyclic amide derivatives
US20060204588A1 (en) *	2005-03-10	2006-09-14	Elan Pharma International Limited	Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
CA2600794C (en)	2005-03-11	2014-08-12	Applera Corporation	Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
AU2006225117A1 (en) *	2005-03-16	2006-09-21	Elan Pharma International Limited	Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
BRPI0606280A2 (pt) *	2005-03-17	2009-06-09	Elan Pharma Int Ltd	composições de bisfosfonato nanoparticulado
JP2008534509A (ja) *	2005-03-23	2008-08-28	エランファーマインターナショナルリミテッド	ナノ粒子副腎皮質ステロイドおよび抗ヒスタミン薬の製剤
US20070224282A1 (en) *	2005-03-28	2007-09-27	Toyama Chemical Co., Ltd.	Fine Dispersion of Sparingly Soluble Drug and Process for Producing the Same
US20090022755A1 (en)	2005-03-31	2009-01-22	Glaxosmithkline Biologicals Sa	Vaccines against chlamydial infection
TW200710091A (en)	2005-04-11	2007-03-16	Tibotec Pharm Ltd	(1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
US20060246141A1 (en) *	2005-04-12	2006-11-02	Elan Pharma International, Limited	Nanoparticulate lipase inhibitor formulations
BRPI0609071A2 (pt) *	2005-04-12	2010-11-16	Elan Pharma Int Ltd	composicão estável de ciclosporina nanoparticulada, método para preparar uma ciclosporina nanoparticulada, uso da composição de ciclosporina nanoparticulada estável, e, composição de liberação controlada
BRPI0607537A2 (pt) *	2005-04-12	2009-09-15	Elan Pharma Int Ltd	formulações de derivado de quinazolina nanoparticulado
JP2008536856A (ja) *	2005-04-13	2008-09-11	エラン・ファルマ・インターナショナル・リミテッド	プロスタグランジン誘導体を含んでなるナノ粒子状且つ徐放性の組成物
US20080305161A1 (en) *	2005-04-13	2008-12-11	Pfizer Inc	Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
NZ561950A (en) *	2005-04-13	2010-09-30	Pfizer Prod Inc	Injectable depot formulations comprising ziprasidone in nanoparticle form with two surface stabilizers
ATE454134T1 (de) *	2005-04-13	2010-01-15	Abbott Gmbh & Co Kg	Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung
ITMI20050739A1 (it) *	2005-04-22	2006-10-23	Effebi Spa	Piastrina di connsessione valvola-attuatore
WO2006116557A1 (en) *	2005-04-25	2006-11-02	Genelabs Technologies, Inc.	Nucleoside compounds for treating viral infections
CA2607715C (en)	2005-04-29	2015-11-24	Glaxosmithkline Biologicals S.A.	Novel method for preventing or treating m tuberculosis infection
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
BRPI0608771A2 (pt) *	2005-05-10	2010-01-26	Elan Pharma Int Ltd	formulações de clopidogrel em nanopartìcula
WO2006132752A1 (en) *	2005-05-10	2006-12-14	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising vitamin k2
TW200716615A (en) *	2005-05-10	2007-05-01	Teva Pharma	Stable micronized candesartan cilexetil and methods for preparing thereof
JP2008540550A (ja) *	2005-05-10	2008-11-20	エラン・ファルマ・インターナショナル・リミテッド	ビタミンｋ２を含むナノ粒子および制御放出組成物
CN101287453A (zh) *	2005-05-16	2008-10-15	依兰药物国际有限公司	包含头孢菌素的毫微粒和控制释放组合物
JP2008545808A (ja) *	2005-05-23	2008-12-18	エラン・ファルマ・インターナショナル・リミテッド	血小板凝集阻害薬を含むナノ粒子状および制御放出組成物
JP2008542396A (ja) *	2005-06-03	2008-11-27	エランファーマインターナショナルリミテッド	ナノ粒子アセトアミノフェン製剤
ES2341996T3 (es) *	2005-06-03	2010-06-30	Elan Pharma International Limited	Formulaciones de mesilato de imatinib en forma de manoparticulas.
US20070042049A1 (en) *	2005-06-03	2007-02-22	Elan Pharma International, Limited	Nanoparticulate benidipine compositions
MX2007015511A (es) *	2005-06-07	2008-03-06	Univ Ramot	Sales novedosas de farmacos sicotropicos conjugados y procesos para prepararlas.
DE112006001606T5 (de)	2005-06-08	2009-07-09	Elan Pharma International Ltd., Athlone	Nanopartikuläre und eine kontrollierte Freisetzung aufweisende Zusammensetzung, die Cefditoren umfassen
WO2006135689A2 (en) *	2005-06-09	2006-12-21	Elan Pharma International, Limited	Nanoparticulate ebastine formulations
CN101237868A (zh) *	2005-06-13	2008-08-06	伊兰制药国际有限公司	纳米粒氯吡格雷和阿司匹林组合制剂
WO2006138421A2 (en) *	2005-06-15	2006-12-28	Elan Pharma International Limited	Nanoparticulate azelnidipine formulations
SG162811A1 (en) *	2005-06-20	2010-07-29	Elan Pharma Int Ltd	Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds
EA200800099A1 (ru) *	2005-06-22	2008-06-30	Элан Фарма Интернэшнл Лтд.	Композиции наночастиц мегестрола
MA28394B1 (fr) *	2005-06-24	2007-01-02	Genelabs Tech Inc	Derives d'heteroaryle pour traitement des virus
US20090028950A1 (en) *	2005-06-29	2009-01-29	Mitsubishi Chemical Corporation	Granule dispersion composition, process for producing the same, and granular material and medicine
US8951560B2 (en) *	2005-06-29	2015-02-10	Dsm Ip Assets B.V.	Isoflavone nanoparticles and use thereof
CA2614409C (en) *	2005-07-07	2014-05-20	Nanotherapeutics, Inc	Process for milling and preparing powders and compositions produced thereby
EP1904041A2 (en) *	2005-07-07	2008-04-02	Elan Pharma International Limited	Nanoparticulate clarithromycin formulations
US20070298109A1 (en) *	2005-07-07	2007-12-27	The Trustees Of The University Of Pennsylvania	Nano-scale devices
CA2615378C (en) *	2005-07-15	2015-02-17	Map Pharmaceuticals, Inc.	Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
WO2007016597A2 (en) *	2005-07-29	2007-02-08	The Regents Of The University Of California	Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
EP1915132A1 (en) *	2005-08-10	2008-04-30	Novartis AG	Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin
KR20080034149A (ko) *	2005-08-10	2008-04-18	노파르티스 아게	7-(ｔ-부톡시)이미노메틸 캄토테신에 대한 제형
GB0516549D0 (en) *	2005-08-12	2005-09-21	Sulaiman Brian	Milling system
US20080193534A1 (en) *	2005-08-12	2008-08-14	Astrazeneca Ab	Process
NZ592132A (en) *	2005-08-31	2012-12-21	Abraxis Bioscience Llc	Composition comprising nanoparticles of docitaxel and a citrate
NO345390B1 (no)	2005-08-31	2021-01-11	Abraxis Bioscience Llc	Preparater omfattende dårlig vannløselige farmasøytiske midler og antimikrobielle midler
WO2007029660A1 (ja) *	2005-09-06	2007-03-15	Astellas Pharma Inc.	腸溶性基剤が表面に吸着した難溶性薬物の微小粒子
JP2009507925A (ja) *	2005-09-13	2009-02-26	エランファーマインターナショナルリミテッド	ナノ粒子タダラフィル製剤
WO2007033372A2 (en)	2005-09-14	2007-03-22	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
JP2009508859A (ja) *	2005-09-15	2009-03-05	エランファーマインターナショナルリミテッド	ナノ粒子アリピプラゾール製剤
US7799530B2 (en)	2005-09-23	2010-09-21	Celera Corporation	Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US8084420B2 (en) *	2005-09-29	2011-12-27	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) *	2005-09-29	2007-04-19	Biodel, Inc.	Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US7713929B2 (en)	2006-04-12	2010-05-11	Biodel Inc.	Rapid acting and long acting insulin combination formulations
WO2007041079A2 (en) *	2005-09-30	2007-04-12	Alza Corporation	Banded controlled release nanoparticle active agent formulation dosage forms and methods
KR101538412B1 (ko)	2005-10-07	2015-07-22	엑셀리시스, 인코포레이티드	ＰＩ３Ｋα의 피리도피리미디논 억제제
CN103819416A (zh)	2005-10-07	2014-05-28	埃克塞里艾克西斯公司	N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
WO2007047305A1 (en) *	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
JP2009511589A (ja) *	2005-10-12	2009-03-19	エランファーマシューティカルズ，インコーポレイテッド	アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法
US7695911B2 (en)	2005-10-26	2010-04-13	Celera Corporation	Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
DE102005053862A1 (de) *	2005-11-04	2007-05-10	Pharmasol Gmbh	Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
CA2631082C (en)	2005-11-23	2015-02-03	Board Of Regents Of The University Of Texas System	Oncogenic ras-specific cytotoxic compound and methods of use thereof
US7858609B2 (en)	2005-11-28	2010-12-28	Marinus Pharmaceuticals	Solid ganaxolone formulations and methods for the making and use thereof
AU2006317530B2 (en) *	2005-11-28	2011-09-01	Imaginot Pty Ltd	Oral therapeutic compound delivery system
EP1968548A2 (en) *	2005-12-02	2008-09-17	Elan Pharma International Limited	Mometasone compositions and methods of making and using the same
AU2006326494A1 (en) *	2005-12-12	2007-06-21	Genelabs Technologies, Inc.	N-(6-membered aromatic ring)-amido anti-viral compounds
US20070197486A1 (en) *	2005-12-20	2007-08-23	Verus Pharmaceuticals, Inc.	Methods and systems for the delivery of corticosteroids
US20070185066A1 (en) *	2005-12-20	2007-08-09	Verus Pharmaceuticals, Inc.	Systems and methods for the delivery of corticosteroids
US20070249572A1 (en) *	2005-12-20	2007-10-25	Verus Pharmaceuticals, Inc.	Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) *	2005-12-20	2007-07-12	Verus Pharmaceuticals, Inc.	Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178049A1 (en) *	2005-12-20	2007-08-02	Verus Pharmaceuticals, Inc.	Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
UA96936C2 (uk)	2005-12-29	2011-12-26	Лексикон Фармасьютикалз, Инк.	Поліциклічні похідні амінокислот і їх застосування
CA2636424A1 (en)	2006-01-09	2007-10-25	The Regents Of The University Of California	Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
DK1981506T6 (da)	2006-01-20	2021-06-14	Janssen Sciences Ireland Unlimited Co	Langtidsbehandling af hiv-infektion med tcm278
JP2009526860A (ja) *	2006-02-15	2009-07-23	ティカレーケメデルアーベー	安定したコルチコステロイド混合物
RU2403059C2 (ru)	2006-02-22	2010-11-10	Маннкайнд Корпорейшн	Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
AU2006338839A1 (en) *	2006-02-23	2007-08-30	Iomedix Sleep International Srl	Compositions and methods for the induction and maintenance of quality sleep
US7649098B2 (en)	2006-02-24	2010-01-19	Lexicon Pharmaceuticals, Inc.	Imidazole-based compounds, compositions comprising them and methods of their use
US8367112B2 (en) *	2006-02-28	2013-02-05	Alkermes Pharma Ireland Limited	Nanoparticulate carverdilol formulations
US20090099175A1 (en) *	2006-03-01	2009-04-16	Arrington Mark P	Phosphodiesterase 10 inhibitors
WO2007103294A2 (en) *	2006-03-07	2007-09-13	Novavax, Inc.	Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US10137083B2 (en)	2006-03-07	2018-11-27	SGN Nanopharma Inc	Ophthalmic preparations
US11311477B2 (en)	2006-03-07	2022-04-26	Sgn Nanopharma Inc.	Ophthalmic preparations
CA2642504A1 (en) *	2006-03-14	2007-09-20	Brian K. Johnson	Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
WO2007113290A1 (en)	2006-04-03	2007-10-11	Tibotec Pharmaceuticals Ltd.	Hiv inhibiting 3,4-dihydro-imidazo[4,5-b]pyridin-5-ones
MX2008013165A (es) *	2006-04-12	2009-01-29	Biodel Inc	Formulaciones de combinacion de insulina de accion rapida y accion larga.
WO2008054508A2 (en) *	2006-04-13	2008-05-08	Alza Corporation	Stable nanosized amorphous drug
ES2654847T3 (es)	2006-04-19	2018-02-15	Novartis Ag	Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R
JP2007306950A (ja)	2006-05-15	2007-11-29	Osaka Univ	薬効成分ナノ粒子分散液の製造方法
US20070275052A1 (en) *	2006-05-24	2007-11-29	Glenmark Pharmaceuticals Limited	Pharmaceutical compositions containing sterol inhibitors
KR20090015994A (ko)	2006-05-30	2009-02-12	엘란 파마 인터내셔널 리미티드	나노입자형 포사코나졸 제제
CN101466317B (zh) *	2006-06-12	2011-08-31	史密夫和内修有限公司	用于进行胫骨切除的系统、方法和装置
EP2037914B1 (en)	2006-06-14	2013-10-23	Intervet International BV	A suspension comprising benzimidazole carbamate and a polysorbate
WO2008002485A2 (en) *	2006-06-23	2008-01-03	Alza Corporation	Increased amorphous stability of poorly water soluble drugs by nanosizing
JP5292288B2 (ja)	2006-06-23	2013-09-18	テイボテク・フアーマシユーチカルズ	Ｔｍｃ２７８の水性懸濁液
RU2009102262A (ru) *	2006-06-26	2010-08-10	Мьючуал Фармасьютикал Компани, Инк. (Us)	Композиции активного агента, способы их получения и способы применения
PL2041088T3 (pl)	2006-06-28	2014-07-31	Amgen Inc	Inhibitory transportera-1 glicyny
EP2054042B8 (en)	2006-06-30	2020-06-10	iCeutica Pty Ltd	Methods for the preparation of biologically active compounds in nanoparticulate form
CN104288103B (zh) *	2006-06-30	2019-10-15	伊休蒂卡有限公司	用于制备纳米粒形式的生物活性化合物的方法
EP2049084A2 (en) *	2006-07-10	2009-04-22	Elan Pharma International Limited	Nanoparticulate sorafenib formulations
ES2393933T3 (es) *	2006-07-17	2013-01-02	Ramot, At Tel Aviv University Ltd.	Conjugados que comprenden un fármaco psicotrópico o un agonista GABA y un ácido orgánico y su uso para el tratamiento del dolor y otros transtornos del SNC
CA2657788A1 (en) *	2006-07-20	2008-01-24	Genelabs Technologies, Inc.	Polycyclic viral inhibitors
WO2008013416A1 (en) *	2006-07-27	2008-01-31	Amorepacific Corporation	Process for preparing powder comprising nanoparticles of sparingly soluble drug
EP2054056A4 (en)	2006-08-16	2010-08-25	J David Gladstone Inst A Testa	SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE
US7994338B2 (en) *	2006-08-16	2011-08-09	The J. David Gladstone Institutes	Small molecule inhibitors of kynurenine-3-monooxygenase
EP2057151A4 (en) *	2006-08-28	2010-07-21	Hetero Drugs Ltd	PROCESS FOR PURIFYING APREPITANT
EP2061433B1 (en) *	2006-09-08	2011-02-16	Johns Hopkins University	Compositions for enhancing transport through mucus
CL2007002567A1 (es)	2006-09-08	2008-02-01	Amgen Inc	Proteinas aisladas de enlace a activina a humana.
US8080645B2 (en)	2007-10-01	2011-12-20	Longhorn Vaccines & Diagnostics Llc	Biological specimen collection/transport compositions and methods
US8097419B2 (en)	2006-09-12	2012-01-17	Longhorn Vaccines & Diagnostics Llc	Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
WO2008085556A2 (en)	2006-09-12	2008-07-17	University Of South Florida	Surfactant-free nanoparticles for drug delivery
US9481912B2 (en)	2006-09-12	2016-11-01	Longhorn Vaccines And Diagnostics, Llc	Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
EP2061583B1 (en) *	2006-09-14	2019-04-10	Yissum Research Development Company, of The Hebrew University of Jerusalem	Organic nanoparticles obtained from microemulsions by solvent evaporation
AR063704A1 (es) *	2006-09-14	2009-02-11	Makhteshim Chem Works Ltd	Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
CL2007002689A1 (es)	2006-09-18	2008-04-18	Vitae Pharmaceuticals Inc	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EP2081548A2 (en) *	2006-09-22	2009-07-29	Labopharm Inc.	Compositions and methods for ph targeted drug delivery
CN1946120B (zh) *	2006-10-20	2010-05-12	华为技术有限公司	实现话单关联的方法及系统
US7910303B2 (en)	2006-10-20	2011-03-22	Celera Corporation	Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
US8946200B2 (en) *	2006-11-02	2015-02-03	Southwest Research Institute	Pharmaceutically active nanosuspensions
WO2008133722A2 (en) *	2006-11-10	2008-11-06	Ucb Pharma S.A.	Anti human sclerostin antibodies
EP2097450A2 (en) *	2006-11-10	2009-09-09	Amgen Inc.	Antibody-based diagnostics and therapeutics
EP2099420B8 (en) *	2006-11-17	2017-03-15	PharmaSol GmbH	Nanocrystals for use in topical cosmetic formulations and method of production thereof
WO2009070744A1 (en)	2007-11-28	2009-06-04	Sequoia Pharmaceuticals, Inc.	Compositions and methods for inhibiting cytochrome p450 2d6
KR20080047956A (ko) *	2006-11-27	2008-05-30	주식회사 엠디바이오알파	발기부전의 치료 및 예방을 위한 약제 조성물
CA2669815A1 (en) *	2006-11-28	2008-06-05	Marinus Pharmaceuticals	Nanoparticulate formulations and methods for the making and use thereof
US20080292695A1 (en) *	2006-12-01	2008-11-27	Kristin Arnold	Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) *	2006-12-01	2009-01-29	Kristin Arnold	Carvedilol forms, compositions, and methods of preparation thereof
US20080138405A1 (en) *	2006-12-06	2008-06-12	Raheja Praveen	Sirolimus nanodispersion
UA99270C2 (en)	2006-12-12	2012-08-10	Лексикон Фармасьютикалз, Инк.	4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
CA2674078C (en) *	2006-12-26	2012-03-20	Femmepharma Holding Company, Inc.	Topical administration of danazol
DE102007001473A1 (de)	2007-01-08	2008-07-10	Andreas Lemke	Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck
EP2109443A4 (en) *	2007-02-09	2012-08-22	Astrazeneca Ab	METHOD FOR PRODUCING A STABLE DISPERSION FROM SOLID AMORPHIC SUBMICRON PARTICLES IN AN AQUEOUS MEDIUM
TW200848039A (en) *	2007-02-09	2008-12-16	Astrazeneca Ab	Pharmaceutical compositions
AU2008214205B2 (en)	2007-02-11	2014-04-24	Map Pharmaceuticals, Inc.	Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
EP2134327A1 (en) *	2007-03-13	2009-12-23	Sandoz AG	Pharmaceutical compositions of poorly soluble drugs
AR065720A1 (es)	2007-03-14	2009-06-24	Tibotec Pharm Ltd	Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
CA2680796A1 (en)	2007-03-14	2008-09-18	Exelixis, Inc.	Inhibitors of the hedgehog pathway
US8911777B2 (en) *	2007-04-04	2014-12-16	Sigmoid Pharma Limited	Pharmaceutical composition of tacrolimus
WO2008124522A2 (en) *	2007-04-04	2008-10-16	Biodel, Inc.	Amylin formulations
TWI405590B (zh)	2007-04-06	2013-08-21	Activus Pharma Co Ltd	微粉碎化有機化合物粒子之製法
HRP20161150T1 (hr)	2007-04-09	2016-11-18	University Of Florida Research Foundation, Inc.	PRIPRAVCI rAAV VEKTORA KOJI IMAJU TIROZIN-MODIFICIRANE CAPSID PROTEINE I POSTUPCI ZA UPORABU
EP2061587A1 (en)	2007-04-26	2009-05-27	Sigmoid Pharma Limited	Manufacture of multiple minicapsules
WO2008132712A2 (en) *	2007-05-01	2008-11-06	Sigmoid Pharma Limited	Combination pharmaceutical compositions
US8703204B2 (en)	2007-05-03	2014-04-22	Bend Research, Inc.	Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en)	2007-05-03	2012-11-13	Bend Research, Inc.	Nanoparticles comprising a drug, ethylcellulose, and a bile salt
CA2723470C (en) *	2007-05-07	2013-12-03	Hale Biopharma Ventures, Llc	Nasal administration of benzodiazepines
US8530463B2 (en) *	2007-05-07	2013-09-10	Hale Biopharma Ventures Llc	Multimodal particulate formulations
US8293769B2 (en)	2007-05-21	2012-10-23	Novartis Ag	CSF-1R inhibitors, compositions, and methods of use
US8722736B2 (en)	2007-05-22	2014-05-13	Baxter International Inc.	Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en)	2007-05-22	2013-04-23	Baxter International Inc.	Colored esmolol concentrate
KR101463011B1 (ko) *	2007-05-31	2014-11-18	더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드	안정한 작용성화된 나노입자를 형성하는 방법
US9545384B2 (en)	2007-06-04	2017-01-17	Bend Research, Inc.	Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US8974827B2 (en)	2007-06-04	2015-03-10	Bend Research, Inc.	Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
RU2327457C1 (ru) *	2007-06-26	2008-06-27	Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи")	Лекарственное средство на основе рифабутина, препарат противомикробного действия, содержащий наночастицы, и способ его получения
EP2170384B1 (en)	2007-07-02	2016-04-13	Etubics Corporation	Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
JP4419157B2 (ja)	2007-07-06	2010-02-24	エム・テクニック株式会社	生体摂取物微粒子の製造方法
AU2008274185B2 (en)	2007-07-12	2014-07-03	Janssen Sciences Ireland Uc	Crystalline form of (E) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
ATE554751T1 (de)	2007-07-13	2012-05-15	Bend Res Inc	Nanopartikel mit einem nicht ionisierbaren polymer und einem anionischen zellulosepolymer
CN101842098A (zh) *	2007-08-10	2010-09-22	基因实验室技术有限公司	用于治疗病毒感染的含氮的二环化学实体
US11041215B2 (en)	2007-08-24	2021-06-22	Longhorn Vaccines And Diagnostics, Llc	PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en)	2007-10-01	2017-06-20	Longhorn Vaccines And Diagnostics, Llc	Biological specimen collection and transport system
US10004799B2 (en)	2007-08-27	2018-06-26	Longhorn Vaccines And Diagnostics, Llc	Composite antigenic sequences and vaccines
EP2772267B1 (en)	2007-08-27	2016-04-27	Longhorn Vaccines and Diagnostics, LLC	Immunogenic compositions and methods
WO2009029729A1 (en) *	2007-08-31	2009-03-05	Genelabs Technologies, Inc.	Amino tricyclic-nucleoside compounds, compositions, and methods of use
WO2009032246A2 (en) *	2007-09-03	2009-03-12	Nanotherapeutics, Inc.	Particulate compositions for delivery of poorly soluble drugs
US20090068266A1 (en) *	2007-09-11	2009-03-12	Raheja Praveen	Sirolimus having specific particle size and pharmaceutical compositions thereof
US20090130210A1 (en) *	2007-09-11	2009-05-21	Raheja Praveen	Pharmaceutical compositions of sirolimus
WO2009035558A1 (en) *	2007-09-12	2009-03-19	Merck & Co., Inc.	Process for the production of a crystalline glucagon receptor antagonist compound
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
WO2009040818A1 (en)	2007-09-25	2009-04-02	Solubest Ltd	Compositions comprising lipophilic active compounds and method for their preparation
US11041216B2 (en)	2007-10-01	2021-06-22	Longhorn Vaccines And Diagnostics, Llc	Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
NZ584308A (en)	2007-10-01	2012-04-27	Longhorn Vaccines & Diagnostics Llc	Biological specimen collection and transport system for nucleic acids and methods of use
KR20100091944A (ko) *	2007-10-11	2010-08-19	주식회사 머젠스	나프토퀴논계 화합물의 미세화 입자를 포함하는 약제 조성물
US8486043B2 (en) *	2007-10-12	2013-07-16	Map Pharmaceuticals, Inc.	Inhalation drug delivery
US9206233B2 (en)	2007-10-19	2015-12-08	University of Pittsburgh—of the Commonwealth System of Higher Education	Templates for controlling synthesis of nanoparticles into discrete assemblies
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
US8642062B2 (en)	2007-10-31	2014-02-04	Abbott Cardiovascular Systems Inc.	Implantable device having a slow dissolving polymer
US8039212B2 (en)	2007-11-05	2011-10-18	Celera Corporation	Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
JP2011503232A (ja)	2007-11-20	2011-01-27	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	免疫応答の調節
US8598165B2 (en)	2007-11-26	2013-12-03	University Of Kansas	Morpholines as selective inhibitors of cytochrome P450 2A13
US9233078B2 (en)	2007-12-06	2016-01-12	Bend Research, Inc.	Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
US9724362B2 (en)	2007-12-06	2017-08-08	Bend Research, Inc.	Pharmaceutical compositions comprising nanoparticles and a resuspending material
KR100961880B1 (ko) *	2007-12-12	2010-06-09	중앙대학교 산학협력단	밀링에 의한 기능성 약물나노입자의 제조방법 및 상기제조방법에 의해 입자 표면이 개질된 약물나노입자 제제
US20090238867A1 (en) *	2007-12-13	2009-09-24	Scott Jenkins	Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
KR20100101656A (ko) *	2007-12-14	2010-09-17	암젠 인크	항-스클레로스틴 항체를 사용한 골절 치료 방법
EA201000947A1 (ru)	2007-12-20	2011-02-28	Новартис Аг	Производные тиазола, применимые в качестве ингибиторов киназы pi3
US9242295B2 (en)	2007-12-21	2016-01-26	The Univeristy Of Texas At Arlington	Bulk nanocomposite magnets and methods of making bulk nanocomposite magnets
US20100054981A1 (en) *	2007-12-21	2010-03-04	Board Of Regents, The University Of Texas System	Magnetic nanoparticles, bulk nanocomposite magnets, and production thereof
US20090197856A1 (en) *	2007-12-21	2009-08-06	Genelabs Technologies, Inc.	Antiviral compounds
KR101405823B1 (ko) *	2007-12-24	2014-06-12	주식회사 케이티앤지생명과학	녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) *	2007-12-28	2009-07-02	주식회사 머젠스	신장질환의 치료 및 예방을 위한 약제 조성물
MX2010007342A (es) *	2008-01-04	2010-08-26	Biodel Inc	Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido.
IL188647A0 (en)	2008-01-08	2008-11-03	Orina Gribova	Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US20090202649A1 (en) *	2008-02-06	2009-08-13	Subhash Gore	Fenofibrate formulations
EP2252578B1 (en)	2008-02-11	2012-08-01	Ramot at Tel Aviv University Ltd.	Conjugates for treating neurodegenerative diseases and disorders
US20090221620A1 (en)	2008-02-20	2009-09-03	Celera Corporation	Gentic polymorphisms associated with stroke, methods of detection and uses thereof
EP2257160B1 (en)	2008-02-21	2017-07-05	Sequoia Pharmaceuticals, Inc.	Diamide inhibitors of cytochrome p450
EP2254555A4 (en) *	2008-02-27	2013-10-09	Reddys Lab Ltd Dr	APREPITANT FORMS WITH INCREASED SOLUBILITY AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
EP2259798B1 (en)	2008-03-05	2013-12-11	Baxter International Inc.	Surface-modified particles and methods for targeted drug delivery
US8404850B2 (en) *	2008-03-13	2013-03-26	Southwest Research Institute	Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
JP2011520779A (ja) *	2008-03-21	2011-07-21	エラン・ファルマ・インターナショナル・リミテッド	イマチニブの部位特異的送達のための組成物および使用の方法
EP2271347B1 (en)	2008-03-28	2016-05-11	Hale Biopharma Ventures, Llc	Administration of benzodiazepine compositions
HU230862B1 (hu) *	2008-04-28	2018-10-29	DARHOLDING Vagyonkezelő Kft	Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
WO2009140341A2 (en) *	2008-05-13	2009-11-19	Dr. Reddy's Laboratories Ltd.	Atorvastatin compositions
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
US20090311335A1 (en) *	2008-06-12	2009-12-17	Scott Jenkins	Combination of a triptan and an nsaid
KR101933816B1 (ko)	2008-06-13	2019-03-29	맨카인드 코포레이션	건조 분말 흡입기 및 약물 투여 시스템
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
GB2460915B (en)	2008-06-16	2011-05-25	Biovascular Inc	Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
JP5479465B2 (ja)	2008-06-20	2014-04-23	マンカインドコーポレイション	吸入努力をリアルタイムにプロファイルする対話式機器および方法
EP2310525B1 (en)	2008-07-09	2014-02-26	Celera Corporation	Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
US20100151037A1 (en) *	2008-08-07	2010-06-17	Yivan Jiang	Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
DE102008037025C5 (de)	2008-08-08	2016-07-07	Jesalis Pharma Gmbh	Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
TWI532497B (zh)	2008-08-11	2016-05-11	曼凱公司	超快起作用胰島素之用途
US8722706B2 (en) *	2008-08-15	2014-05-13	Southwest Research Institute	Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
NZ590746A (en)	2008-08-19	2012-10-26	Xenoport Inc	Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
US9700525B2 (en)	2008-08-20	2017-07-11	Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College	Continuous local slow-release of therapeutics for head and neck problems and upper aerodigestive disorders
AU2009291755B2 (en)	2008-09-10	2016-04-21	Biochemics, Inc.	Ibuprofen for topical administration
KR101455446B1 (ko) *	2008-09-19	2014-10-27	액티버스 파마 컴퍼니 리미티드	의료용 복합 유기 화합물 분체, 그 제조 방법 및 현탁액
TWI580441B (zh) *	2008-09-19	2017-05-01	愛爾康研究有限公司	穩定的藥學次微米懸浮液及其形成方法
GB0818403D0 (en) *	2008-10-08	2008-11-12	Univ Leuven Kath	Aqueous electrophoretic deposition
US8309134B2 (en) *	2008-10-03	2012-11-13	Southwest Research Institute	Modified calcium phosphate nanoparticle formation
WO2010040648A2 (en) *	2008-10-06	2010-04-15	Katholieke Universiteit Leuven, K.U.Leuven R&D	Functional layers of biomolecules and living cells, and a novel system to produce such
US20100098770A1 (en) *	2008-10-16	2010-04-22	Manikandan Ramalingam	Sirolimus pharmaceutical formulations
US8277697B2 (en) *	2008-10-29	2012-10-02	Global Oled Technology Llc	Color filter element with improved colorant dispersion
RU2431495C2 (ru) *	2008-11-19	2011-10-20	Общество с ограниченной ответственностью "Биолит"	Жаропонижающее средство и способ его получения
WO2010065760A1 (en)	2008-12-04	2010-06-10	Exelixis, Inc.	Imidazo [1,2a] pyridine derivatives, their use as s1p1 agonists and methods for their production
MX2011006307A (es)	2008-12-15	2011-10-14	Banner Pharmacaps Inc	Metodos para aumentar la liberacion y absorcion de agentes activos insolubles en agua.
JP2012512255A (ja)	2008-12-17	2012-05-31	アムジエン・インコーポレーテツド	ホスホジエステラーゼ１０阻害剤としてのアミノピリジンおよびカルボキシピリジン化合物
US8551973B2 (en)	2008-12-23	2013-10-08	Gilead Pharmasset Llc	Nucleoside analogs
AR074897A1 (es)	2008-12-23	2011-02-23	Pharmasset Inc	Fosforamidatos de nucleosidos
EP2671888A1 (en)	2008-12-23	2013-12-11	Gilead Pharmasset LLC	3',5'-cyclic nucleoside phosphate analogues
US20100159010A1 (en) *	2008-12-24	2010-06-24	Mutual Pharmaceutical Company, Inc.	Active Agent Formulations, Methods of Making, and Methods of Use
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
US8501759B2 (en)	2009-01-02	2013-08-06	Fournier Laboratories Ireland Limited	Use of fibrates
CA2782655A1 (en)	2009-01-06	2010-07-15	Pharmanova, Inc.	Nanoparticle pharmaceutical formulations
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US20100183687A1 (en) *	2009-01-22	2010-07-22	Cox D Phillip	Process for preparing particles of opioids and compositions produced thereby
AR075180A1 (es) *	2009-01-29	2011-03-16	Novartis Ag	Formulaciones orales solidas de una pirido-pirimidinona
CN102365098A (zh)	2009-01-30	2012-02-29	明治制果药业株式会社	细粉状药物组合物
WO2010091198A1 (en)	2009-02-06	2010-08-12	University Of Southern California	Therapeutic compositions comprising monoterpenes
WO2010091104A1 (en)	2009-02-06	2010-08-12	Exelixis, Inc.	Glucosylceramide synthase inhibitors
WO2010091164A1 (en)	2009-02-06	2010-08-12	Exelixis, Inc.	Inhibitors of glucosylceramide synthase
US20100204265A1 (en) *	2009-02-09	2010-08-12	Genelabs Technologies, Inc.	Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
EP2398791A1 (en)	2009-02-18	2011-12-28	Amgen, Inc	INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS
EP4578502A2 (en)	2009-02-26	2025-07-02	Glaxo Group Limited	Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
US9060927B2 (en) *	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
US11096901B2 (en)	2009-03-06	2021-08-24	Metaqor Llc	Dynamic bio-nanoparticle platforms
WO2010105094A1 (en)	2009-03-11	2010-09-16	Mannkind Corporation	Apparatus, system and method for measuring resistance of an inhaler
JP5841044B2 (ja)	2009-03-23	2016-01-06	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	複合糖質ワクチン
US7828996B1 (en) *	2009-03-27	2010-11-09	Abbott Cardiovascular Systems Inc.	Method for the manufacture of stable, nano-sized particles
WO2010114770A1 (en) *	2009-03-30	2010-10-07	Cerulean Pharma Inc.	Polymer-agent conjugates, particles, compositions, and related methods of use
US20100249071A1 (en)	2009-03-30	2010-09-30	Exelixis, Inc.	Modulators of S1P and Methods of Making And Using
KR20120022895A (ko) *	2009-04-09	2012-03-12	엘커메스 파마 아일랜드 리미티드	약물 전달 조성물
US20100268187A1 (en) *	2009-04-17	2010-10-21	Ranbaxy Laboratories Limited	Packaging for sirolimus and composition thereof
UA106231C2 (uk)	2009-04-24	2014-08-11	Айсьютика Пти Лтд	Разова доза фармацевтичної композиції індометацину (варіанти)
NZ620887A (en)	2009-04-24	2015-08-28	Iceutica Pty Ltd	A novel formulation of diclofenac
US10952965B2 (en) *	2009-05-15	2021-03-23	Baxter International Inc.	Compositions and methods for drug delivery
US20100291221A1 (en) *	2009-05-15	2010-11-18	Robert Owen Cook	Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
EP2253306A1 (en)	2009-05-18	2010-11-24	Royal College of Surgeons in Ireland	Orodispersible dosage forms containing solid drug dispersions
EP2432455B1 (en)	2009-05-18	2014-11-12	Sigmoid Pharma Limited	Composition comprising oil drops
TWI576352B (zh)	2009-05-20	2017-04-01	基利法瑪席特有限責任公司	核苷磷醯胺
WO2010135568A1 (en)	2009-05-22	2010-11-25	Exelixis, Inc.	Benzoxazepines as inhibitors of mtor and their use to treat cancer
WO2010135714A2 (en)	2009-05-22	2010-11-25	The Methodist Hospital Research Institute	Methods for modulating adipocyte expression using microrna compositions
FR2945950A1 (fr)	2009-05-27	2010-12-03	Elan Pharma Int Ltd	Compositions de nanoparticules anticancereuses et procedes pour les preparer
JP6072539B2 (ja)	2009-05-27	2017-02-01	アルカーメスファーマアイルランドリミテッド	ナノ粒子活性物質組成物におけるフレーク状凝集の軽減
RU2403049C1 (ru) *	2009-06-04	2010-11-10	Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Федерального агентства по здравоохранению и социальному развитию (ГОУВПО ММА им. И.М. Сеченова Росздрава)	Способ получения таблеток эритромицина
TR200904500A2 (tr)	2009-06-10	2009-10-21	Öner Levent	Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
KR20190090092A (ko)	2009-06-12	2019-07-31	맨카인드 코포레이션	한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CN102480958B (zh)	2009-06-12	2015-08-19	Cynapsus疗法有限公司	舌下阿扑吗啡
SMT202000093T1 (it)	2009-06-16	2020-03-13	Pfizer	Forme di dosaggio di apixaban
WO2011005496A2 (en)	2009-06-22	2011-01-13	Massachusetts Eye & Ear Infirmary	Islet1 (isl1) and hearing loss
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
US20110003000A1 (en) *	2009-07-06	2011-01-06	Femmepharma Holding Company, Inc.	Transvaginal Delivery of Drugs
RU2528895C2 (ru)	2009-07-09	2014-09-20	Ошади Драг Администрейшн Лтд.	Композиции матриксных носителей, способы и применения
WO2011006066A1 (en)	2009-07-10	2011-01-13	Ironwood Pharmaceuticals, Inc.	Cb receptor agonists
EP2283824B1 (en)	2009-07-30	2017-04-19	Special Products Line S.p.A.	Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
AR077692A1 (es)	2009-08-06	2011-09-14	Vitae Pharmaceuticals Inc	Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
BR112012002963A2 (pt)	2009-08-12	2017-10-24	Sigmoid Pharma Ltd	composições imunomoduladoras compreendendo uma matriz de polímero e uma fase oleosa
EP2298296A1 (en)	2009-08-25	2011-03-23	CNRS Centre National De La Recherche Scientifique	Composition and method for treating cognitive impairments in down syndrome subjects
WO2011025905A1 (en)	2009-08-28	2011-03-03	Research Development Foundation	Urocortin 2 analogs and uses thereof
US9775819B2 (en) *	2009-09-16	2017-10-03	R.P. Scherer Technologies, Llc	Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
UY32919A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
JP5920875B2 (ja) *	2009-10-16	2016-05-18	ライフケアイノベーションズプライベートリミテッド	真菌感染症を治療するための新規な製剤
WO2011049629A2 (en)	2009-10-22	2011-04-28	Api Genesis, Llc	Methods of making and using compositions comprising flavonoids
EP2496295A1 (en)	2009-11-03	2012-09-12	MannKind Corporation	An apparatus and method for simulating inhalation efforts
EP2496231A1 (en)	2009-11-05	2012-09-12	Lexicon Pharmaceuticals, Inc.	Tryptophan hydroxylase inhibitors for the treatment of cancer
CA2780292A1 (en) *	2009-11-10	2011-05-19	Celgene Corporation	Nanosus pens ion of a poorly soluble drug made by microfluidization process
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
WO2011068872A2 (en)	2009-12-03	2011-06-09	Alcon Research, Ltd.	Carboxyvinyl polymer-containing nanoparticle suspension
BR112012013639A2 (pt) *	2009-12-09	2017-04-04	Bar-Ilan Univ	"métodos pára melhorar funções congnitivas"
JP2013513605A (ja)	2009-12-11	2013-04-22	エグゼリクシス，インコーポレイテッド	Ｔｇｒ５アゴニスト
US20120288507A1 (en)	2009-12-18	2012-11-15	Amgen Inc.	Wise binding agents and epitopes
JP5816194B2 (ja)	2009-12-22	2015-11-18	レオファーマアクティーゼルスカブ	カルシポトリオール一水和物ナノクリスタル
TW201130810A (en)	2009-12-23	2011-09-16	Ironwood Pharmaceuticals Inc	CRTH2 modulators
MX2012008790A (es)	2010-01-27	2012-08-17	Glaxosmithkline Biolog Sa	Antigenos de tuberculosis modificados.
US9028873B2 (en) *	2010-02-08	2015-05-12	Southwest Research Institute	Nanoparticles for drug delivery to the central nervous system
WO2011100324A1 (en)	2010-02-09	2011-08-18	Ironwood Pharmaceuticals Inc.	Cannabinoid receptor agonists
TW201139436A (en)	2010-02-09	2011-11-16	Exelixis Inc	Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
WO2011100359A1 (en)	2010-02-09	2011-08-18	Ironwood Pharmaceuticals, Inc.	Cannabinoid agonists
WO2011100285A1 (en)	2010-02-10	2011-08-18	Lexicon Pharmaceuticals, Inc.	Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
EP2536689A1 (en)	2010-02-17	2012-12-26	Amgen Inc.	Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
BR112012019635A2 (pt)	2010-02-22	2016-05-03	Hoffmann La Roche	compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso
JP2013520488A (ja) *	2010-02-24	2013-06-06	ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド	ペルフェナジン−ｇａｂａのトリメシラート塩の結晶性形態物及びその製法方法
WO2011111794A1 (ja) *	2010-03-11	2011-09-15	浜松ホトニクス株式会社	微粒子分散液製造方法および微粒子分散液製造装置
CN102858682B (zh)	2010-03-22	2014-07-16	株式会社Bio-Synectics	纳米颗粒制备方法
WO2011123645A2 (en)	2010-03-31	2011-10-06	Pharmasset, Inc.	Nucleoside phosphoramidates
PL2609923T4 (pl)	2010-03-31	2017-11-30	Gilead Pharmasset Llc	Proces krystalizacji 2-(((s)-(perfluorofenoksy) (fenoksy)fosforylo)amino)propanianu (s)-izopropylu
US8563530B2 (en)	2010-03-31	2013-10-22	Gilead Pharmassel LLC	Purine nucleoside phosphoramidate
DE102010003711B4 (de) *	2010-04-08	2015-04-09	Jesalis Pharma Gmbh	Verfahren zur Herstellung kristalliner Wirkstoffpartikel
US20110269735A1 (en)	2010-04-19	2011-11-03	Celera Corporation	Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
HUE041571T2 (hu)	2010-04-23	2019-05-28	Univ Florida	RAAV-guanilát-cikláz-készítmények és ejárások 1-es típusú Leber-féle veleszületett vakság (LCA1) kezelésére
US9101541B2 (en)	2010-04-28	2015-08-11	Cadila Healthcare Limited	Stable solid pharmaceutical matrix compositions of sirolimus
US20130116333A1 (en) *	2010-05-05	2013-05-09	Ratiopharm Gmbh	Solid tapentadol in non-crystalline form
US8765737B1 (en)	2010-05-11	2014-07-01	Demerx, Inc.	Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en)	2010-05-11	2013-01-29	Demerx, Inc.	Substituted noribogaine
US9394294B2 (en)	2010-05-11	2016-07-19	Demerx, Inc.	Methods and compositions for preparing and purifying noribogaine
EP2569302A1 (en)	2010-05-13	2013-03-20	Amgen, Inc	Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
CA2798490A1 (en)	2010-05-13	2011-11-17	Amgen Inc.	Nitrogen heterocyclic compounds useful as pde10 inhibitors
AU2011253143A1 (en)	2010-05-13	2012-12-06	Amgen Inc.	Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
AU2011253058A1 (en)	2010-05-13	2012-12-06	Amgen Inc.	Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
SMT202000095T1 (it)	2010-05-14	2020-03-13	Amgen Inc	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2011146583A2 (en)	2010-05-19	2011-11-24	Elan Pharma International Limited	Nanoparticulate cinacalcet formulations
HUP1000325A2 (en)	2010-06-18	2012-01-30	Druggability Technologies Ip Holdco Jersey Ltd	Nanostructured aprepitant compositions and process for their preparation
BR112012033060A2 (pt)	2010-06-21	2018-02-27	Mannkind Corp	métodos de sistema de liberação de fármaco em pó seco
US8802832B2 (en)	2010-06-22	2014-08-12	Demerx, Inc.	Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en)	2010-06-22	2014-06-03	Demerx, Inc.	N-substituted noribogaine prodrugs
US8637648B1 (en)	2010-06-22	2014-01-28	Demerx, Inc.	Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en)	2010-06-22	2017-03-07	Demerx, Inc.	N-substituted noribogaine prodrugs
EP2588112B1 (en)	2010-06-30	2017-09-27	Victoria Link Ltd	Methods and compositions for treatment of multiple sclerosis
KR20130098301A (ko)	2010-07-09	2013-09-04	엑셀리시스, 인코포레이티드	암 치료를 위한 키나제 억제제들의 병용물
US20130259830A1 (en)	2010-07-12	2013-10-03	Ironwood Pharmaceuticals, Inc.	Crth2 modulators
WO2012009137A1 (en)	2010-07-12	2012-01-19	Ironwood Pharmaceuticals, Inc.	Crth2 modulators
UA111065C2 (uk)	2010-07-23	2016-03-25	Демеркс, Інк.	Композиції норибогаїну
AU2011291506B2 (en)	2010-08-19	2016-07-28	Buck Institute For Age Research	Methods of treating mild cognitive impairment (mci) and related disorders
AU2011302216A1 (en)	2010-09-14	2013-04-04	Exelixis, Inc.	Phtalazine derivatives as JAK1 inhibitors
ES2612503T3 (es)	2010-09-14	2017-05-17	Exelixis, Inc.	Compuestos 9H-purina como inhibidores de PI3K-delta y métodos para su preparación
EP2616442B8 (en)	2010-09-14	2018-10-17	Exelixis, Inc.	Inhibitors of pi3k-delta and methods of their use and manufacture
WO2012038963A1 (en)	2010-09-22	2012-03-29	Ramot At Tel-Aviv University Ltd.	An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
BR112013006651A2 (pt)	2010-09-23	2017-07-18	Nuformix Ltd	composição e cocristal de aprepitante l-prolina
JP2013537918A (ja)	2010-09-27	2013-10-07	エクセリクシス，インク．	去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
DK2621481T4 (da)	2010-09-27	2023-01-09	Exelixis Inc	Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
EP2621482A1 (en)	2010-09-27	2013-08-07	Exelixis, Inc.	Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
EP2627317A4 (en) *	2010-10-15	2014-08-20	Glaxo Group Ltd	MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE
US20120108651A1 (en)	2010-11-02	2012-05-03	Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL)	Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
RU2632445C2 (ru) *	2010-11-02	2017-10-04	Боард Оф Реджентс Оф Де Юниверсити Оф Небраска	Композиции и способы доставки терапевтических средств
WO2012061337A1 (en)	2010-11-02	2012-05-10	Exelixis, Inc.	Fgfr2 modulators
WO2012065057A2 (en)	2010-11-12	2012-05-18	Exelixis, Inc.	Phosphatidylinositol 3-kinase inhibitors and methods of their use
WO2012065019A2 (en)	2010-11-12	2012-05-18	Exelixis, Inc.	Pyridopyrimidinone inhibitors of p13k alpha
EP2640367A2 (en)	2010-11-15	2013-09-25	Exelixis, Inc.	Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
EP2640366A2 (en)	2010-11-15	2013-09-25	Exelixis, Inc.	Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012071509A2 (en)	2010-11-24	2012-05-31	Exelixis, Inc.	Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
GB201020032D0 (en)	2010-11-25	2011-01-12	Sigmoid Pharma Ltd	Composition
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
EP2646453A1 (en)	2010-11-30	2013-10-09	Gilead Pharmasset LLC	Compounds
JP2014500277A (ja)	2010-12-09	2014-01-09	アムジエン・インコーポレーテツド	Ｐｉｍ阻害剤としての二環式化合物
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
CA3115378A1 (en)	2010-12-16	2012-06-21	Sunovion Pharmaceuticals Inc.	Sublingual films comprising apomorphine and an organic base
EP2658857B1 (en)	2010-12-29	2016-11-02	Inhibitex, Inc.	Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
EP2661434A4 (en)	2011-01-06	2014-07-09	Beta Pharma Canada Inc	NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER
EP2481740B1 (en)	2011-01-26	2015-11-04	DemeRx, Inc.	Methods and compositions for preparing noribogaine from voacangine
EA201391248A1 (ru)	2011-03-01	2014-05-30	Эмджен Инк.	Биспецифические связывающие агенты
JP2014510105A (ja)	2011-03-22	2014-04-24	アムジエン・インコーポレーテツド	Ｐｉｍ阻害剤としてのアゾール化合物
PE20140437A1 (es)	2011-03-25	2014-04-17	Amgen Inc	Formulaciones de anticuerpos
ES2625858T3 (es)	2011-04-01	2017-07-20	Mannkind Corporation	Paquete de tipo blíster para cartuchos farmacéuticos
ES2823805T3 (es)	2011-04-15	2021-05-10	Janssen Pharmaceutica Nv	Nanosuspensiones de fármacos secadas por congelamiento
US8883497B2 (en)	2011-04-28	2014-11-11	University Of Southern California	Human myeloid derived suppressor cell cancer markers
EP2702063A1 (en)	2011-04-29	2014-03-05	Amgen Inc.	Bicyclic pyridazine compounds as pim inhibitors
EA201391606A1 (ru)	2011-04-29	2016-01-29	Экселиксис, Инк.	Способ лечения лимфомы посредством пиридопиримидиноновых ингибиторов pi3k/mtor
WO2012154879A2 (en)	2011-05-09	2012-11-15	Van Andel Research Institute	Autophagy inhibitors
JP2014521381A (ja)	2011-05-13	2014-08-28	ブロンカステクノロジーズ，インコーポレイテッド	組織の切除のための方法およびデバイス
US8709034B2 (en)	2011-05-13	2014-04-29	Broncus Medical Inc.	Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
US20140107151A1 (en)	2011-05-17	2014-04-17	Principia Biophama Inc.	Tyrosine kinase inhibitors
US9376438B2 (en)	2011-05-17	2016-06-28	Principia Biopharma, Inc.	Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
WO2012158785A1 (en)	2011-05-17	2012-11-22	Principia Biopharma Inc.	Azaindole derivatives as tyrosine kinase inhibitors
JP5974084B2 (ja)	2011-05-17	2016-08-23	プリンシピアバイオファーマインコーポレイテッド	チロシンキナーゼ阻害剤
PT3415139T (pt)	2011-06-14	2022-06-20	Neurelis Inc	Administração de benzodiazepina
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
EP2723365A1 (en)	2011-06-21	2014-04-30	Oncofactor Corporation	Compositions and methods for the therapy and diagnosis of cancer
JP5978296B2 (ja)	2011-06-28	2016-08-24	フジアン・ミンドン・レジュヴネイション・ファーマスーティカル・カンパニー・リミテッド	抗アレルギ性ベンゾシクロヘプタチオフェン誘導体
ES2624984T3 (es)	2011-07-15	2017-07-18	Viiv Healthcare Uk Limited	Derivados de ácido 2-(pirrolo[2,3-b]piridin-5-il)-2-(t-butoxi)-acético como inhibidores de la replicación del VIH para el tratamiento del SIDA
WO2013016174A1 (en)	2011-07-22	2013-01-31	Chemocentryx, Inc.	A crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
CA2842753A1 (en)	2011-07-22	2013-01-31	Chemocentryx, Inc.	Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
US10538584B2 (en)	2011-08-04	2020-01-21	Amgen Inc.	Methods for treating bone gap defects
US9617274B1 (en)	2011-08-26	2017-04-11	Demerx, Inc.	Synthetic noribogaine
KR20190075172A (ko)	2011-09-01	2019-06-28	글락소 그룹 리미티드	신규한 결정 형태
EP2755654A1 (en)	2011-09-14	2014-07-23	Exelixis, Inc.	Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
KR101794032B1 (ko)	2011-09-21	2017-11-07	(주)바이오시네틱스	나노입자 제조방법
CN103957915A (zh)	2011-09-22	2014-07-30	埃克塞里艾克西斯公司	治疗骨质疏松症的方法
ES2632443T3 (es)	2011-09-22	2017-09-13	Viiv Healthcare Uk Limited	Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH
MX356017B (es) *	2011-09-29	2018-05-08	Plx Opco Inc	Portadores dependientes de ph para la liberacion dirigida de productos farmaceuticos a lo largo del tracto gastrointestinal, composiciones de los mismos, y fabricacion y uso de las mismas.
WO2013056067A1 (en)	2011-10-13	2013-04-18	Exelixis, Inc.	Compounds for use in the treatment of basal cell carcinoma
TWI580442B (zh) *	2011-10-19	2017-05-01	傑特大學	醫藥毫微懸浮物
US9233159B2 (en)	2011-10-24	2016-01-12	Mannkind Corporation	Methods and compositions for treating pain
KR20140096083A (ko)	2011-11-01	2014-08-04	엑셀리시스, 인코포레이티드	림프증식성 악성종양의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제로서 ｎ（3｛［（3｛［2클로로5（메톡시）페닐］아미노｝퀴녹살린2일）아미노］설포닐｝페닐）2메틸알라닌아미드
WO2013067306A1 (en)	2011-11-02	2013-05-10	Exelixis, Inc.	Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
TWI662962B (zh)	2011-11-08	2019-06-21	艾克塞里克斯公司	治療癌症之方法
KR20140094597A (ko)	2011-11-08	2014-07-30	엑셀리시스, 인코포레이티드	암 치료를 정량하는 방법
CN107880101B (zh)	2011-11-11	2021-12-21	弗雷德哈钦森癌症研究中心	针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
JP2015501802A (ja)	2011-11-17	2015-01-19	ザリージェンツオブザユニバーシティオブコロラド，アボディーコーポレイトＴＨＥＲＥＧＥＮＴＳＯＦＴＨＥＵＮＩＶＥＲＳＩＴＹＯＦＣＯＬＯＲＡＤＯ，ａｂｏｄｙｃｏｒｐｏｒａｔｅ	眼への薬物送達を向上させるための方法および組成物、ならびに徐放性送達製剤
WO2013078235A1 (en)	2011-11-23	2013-05-30	Broncus Medical Inc	Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
CA2892832C (en)	2011-11-25	2020-04-14	Nuformix Limited	Aprepitant l-proline solvates - compositions and cocrystals
EP2788003A4 (en)	2011-12-09	2015-05-27	Demerx Inc	PHOSPHATESTER OF NORIBOGAIN
JO3387B1 (ar)	2011-12-16	2019-03-13	Glaxosmithkline Llc	مشتقات بيتولين
ES2813524T3 (es)	2011-12-28	2021-03-24	Amgen Inc	Método para tratar la pérdida de hueso alveolar mediante el uso de anticuerpos antiesclerostina
US8877921B2 (en)	2012-01-25	2014-11-04	Demerx, Inc.	Synthetic voacangine
US9150584B2 (en)	2012-01-25	2015-10-06	Demerx, Inc.	Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
CA3207612A1 (en)	2012-01-26	2013-08-01	Longhorn Vaccines And Diagnostics, Llc	Composite antigenic sequences and vaccines
WO2013130660A1 (en)	2012-02-28	2013-09-06	Amgen Inc.	Amides as pim inhibitors
TW201348231A (zh)	2012-02-29	2013-12-01	Amgen Inc	雜雙環化合物
SI2827710T1 (sl)	2012-03-19	2020-04-30	Cidara Therapeutics, Inc.	Režimi odmerjanja za spojine razreda ehinokandin
AU2013235491A1 (en)	2012-03-22	2014-09-11	Nanotherapeutics, Inc.	Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
KR101956586B1 (ko) *	2012-03-27	2019-03-11	일양약품주식회사	약제학적 조성물 및 이의 제조방법
US20130303763A1 (en)	2012-03-30	2013-11-14	Michael D. Gershon	Methods and compositions for the treatment of necrotizing enterocolitis
US20150080381A1 (en)	2012-04-12	2015-03-19	Ironwood Pharmaceuticals, Inc.	Methods of treating alopecia and acne
US9452107B2 (en)	2012-04-16	2016-09-27	New Jersey Institute Of Technology	Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
US9861624B2 (en)	2012-05-02	2018-01-09	Exelixis, Inc.	Method of treating cancer
US9827191B2 (en)	2012-05-03	2017-11-28	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
JP6360040B2 (ja)	2012-05-03	2018-07-18	カラファーマシューティカルズインコーポレイテッド	粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法
WO2013166385A1 (en)	2012-05-03	2013-11-07	Kala Pharmaceuticals, Inc.	Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en)	2012-05-03	2023-03-07	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
BR112014028431B1 (pt)	2012-05-11	2022-01-11	Activus Pharma Co., Ltd	Nanopó de composto orgânico, método para produzir o mesmo e suspensão
WO2013173417A2 (en)	2012-05-17	2013-11-21	Transtech Pharma, Inc.	Glucokinase activator compositions for the treatment of diabetes
NZ713828A (en)	2012-06-04	2017-05-26	Pharmacyclics Llc	Crystalline forms of a bruton’s tyrosine kinase inhibitor
AR091436A1 (es)	2012-06-14	2015-02-04	Amgen Inc	Compuestos de azetidina y piperidina utiles como inhibidores de pde10
CN110123763A (zh)	2012-06-21	2019-08-16	法斯瑞斯公司	靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法
EP3626267A1 (en)	2012-07-05	2020-03-25	UCB Pharma, S.A.	Treatment for bone diseases
GB201212010D0 (en)	2012-07-05	2012-08-22	Sigmoid Pharma Ltd	Formulations
AU2013288369B2 (en)	2012-07-12	2018-03-29	Viiv Healthcare Uk Limited	Compounds and methods for treating HIV
US9802012B2 (en)	2012-07-12	2017-10-31	Mannkind Corporation	Dry powder drug delivery system and methods
JOP20130213B1 (ar)	2012-07-17	2021-08-17	Takeda Pharmaceuticals Co	معارضات لمستقبلht3-5
WO2014022752A1 (en)	2012-08-03	2014-02-06	Amgen Inc.	Macrocycles as pim inhibitors
JP6193374B2 (ja)	2012-08-13	2017-09-06	武田薬品工業株式会社	Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体
JP2015527372A (ja)	2012-08-22	2015-09-17	ゼノポート，インコーポレイティド	副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
JP2015526476A (ja)	2012-08-22	2015-09-10	ゼノポート，インコーポレイティド	メチル水素フマレートの経口剤形およびそのプロドラッグ
US9605276B2 (en)	2012-08-24	2017-03-28	Etubics Corporation	Replication defective adenovirus vector in vaccination
CA2922849A1 (en)	2012-08-31	2014-03-06	Ixchel Pharma, Llc	Agents useful for treating obesity, diabetes and related disorders
JP2015526520A (ja)	2012-08-31	2015-09-10	プリンシピアバイオファーマインコーポレイテッド	Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体
SMT201900344T1 (it)	2012-09-10	2019-07-11	Principia Biopharma Inc	Composti di pirazolopirimidina come inibitori di chinasi
WO2014066856A1 (en)	2012-10-26	2014-05-01	Mannkind Corporation	Inhalable influenza vaccine compositions and methods
KR20150085068A (ko)	2012-11-20	2015-07-22	프린시피아 바이오파마, 인코퍼레이티드	Jak3 저해제로서의 아자인돌 유도체
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
EP2925764B1 (en)	2012-11-30	2023-03-01	Sanford-Burnham Medical Research Institute	Inhibitor of apoptosis protein (iap) antagonists
WO2014091318A1 (en)	2012-12-11	2014-06-19	Lupin Atlantis Holdings, S.A.	Reduced dose pharmaceutical compositions of fenofibrate
WO2014100021A1 (en)	2012-12-17	2014-06-26	Exelixis, Inc.	Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
US9045481B2 (en)	2012-12-20	2015-06-02	Demerx, Inc.	Substituted noribogaine
CA2896133A1 (en)	2012-12-20	2014-06-26	Demerx, Inc.	Substituted noribogaine
US8940728B2 (en)	2012-12-20	2015-01-27	Demerx, Inc.	Substituted noribogaine
HK1218553A1 (zh)	2013-02-01	2017-02-24	Santa Maria Biotherapeutics, Inc.	抗激活素a化合物對受試者的施用
EP2961533B1 (en) *	2013-02-28	2021-10-13	Sun Chemical Corporation	Continuous contained-media micromedia milling process
HK1213780A1 (zh) *	2013-03-04	2016-07-15	Vtv治疗有限责任公司	穩定的葡萄糖激酶活化劑組合物
WO2014160177A2 (en)	2013-03-13	2014-10-02	Exelixis, Inc.	Quinazoline inhibitors of pi3k
EP2970149B1 (en)	2013-03-15	2019-08-21	MannKind Corporation	Microcrystalline diketopiperazine compositions and methods
US9732068B1 (en)	2013-03-15	2017-08-15	GenSyn Technologies, Inc.	System for crystalizing chemical compounds and methodologies for utilizing the same
JP2016512226A (ja)	2013-03-15	2016-04-25	グラクソスミスクラインバイオロジカルズソシエテアノニム	緩衝化アミノアルキルグルコサミニドホスフェート誘導体を含有する組成物及び免疫応答を増強するためのその使用
US10179118B2 (en)	2013-03-24	2019-01-15	Arbor Pharmaceuticals, Llc	Pharmaceutical compositions of dimethyl fumarate
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (hu)	2013-04-05	2019-05-28	Boehringer Ingelheim Int	Az empagliflozin terápiás alkalmazásai
HK1213818A1 (zh)	2013-04-05	2016-07-15	勃林格殷格翰国际有限公司	依帕列净的治疗用途
SI2986304T1 (sl)	2013-04-18	2022-04-29	Boehringer Ingelheim International Gmbh	Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
CA2911706A1 (en)	2013-05-09	2014-11-13	Principia Biopharma Inc.	Quinolone derivatives as fibroblast growth factor inhibitors
WO2014197860A1 (en)	2013-06-07	2014-12-11	Xenoport, Inc.	Method of making monomethyl fumarate
BR112015030341A2 (pt)	2013-06-20	2017-07-25	Glenmark Pharmaceuticals Sa	formulações de nanoparticulado e processo para prepará-las, composição farmacêutica e uso de composto ou seu sal farmaceuticamente aceitável e estabilizante de superfície
US9421182B2 (en)	2013-06-21	2016-08-23	Xenoport, Inc.	Cocrystals of dimethyl fumarate
KR102321339B1 (ko)	2013-07-18	2021-11-02	맨카인드 코포레이션	열-안정성 건조 분말 약제학적 조성물 및 방법
WO2015021064A1 (en)	2013-08-05	2015-02-12	Mannkind Corporation	Insufflation apparatus and methods
JP2016534133A (ja)	2013-09-06	2016-11-04	ゼノポート，インコーポレイティド	（ｎ，ｎ−ジエチルカルバモイル）メチルメチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
WO2015042294A1 (en)	2013-09-18	2015-03-26	Xenoport, Inc.	Nanoparticle compositions of dimethyl fumarate
GB201319791D0 (en)	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
WO2015071841A1 (en)	2013-11-12	2015-05-21	Druggability Technologies Holdings Limited	Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP2878311A1 (en)	2013-11-27	2015-06-03	Freund Pharmatec Ltd.	Solubility Enhancement for Hydrophobic Drugs
CA2935944A1 (en)	2014-01-09	2015-07-16	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Substituted benzoxazine and related compounds
WO2015108945A2 (en)	2014-01-14	2015-07-23	Board Of Regents Of The University Of Nebraska	Compositions and methods for the delivery of therapeutics
US10898581B2 (en)	2014-01-16	2021-01-26	The Brigham And Women's Hospital, Inc.	Targeted delivery of immunoregulatory drugs
BR112016018948B1 (pt)	2014-02-21	2023-01-17	Principia Biopharma Inc	Uso de composto ou sal farmaceuticamente aceitável, ácido sulfônico ou sal de ácido carboxílico de composto, forma amorfa de sal farmaceuticamente aceitável de composto, composição farmacêutica e respectivo uso
WO2015134210A1 (en)	2014-03-03	2015-09-11	Principia Biopharma, Inc.	BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
US20150250776A1 (en)	2014-03-05	2015-09-10	Nanotherapeutics, Inc.	Compositions and methods for oral delivery of encapsulated 3-aminopyridine-2-carboxaldehyde particles
US9999672B2 (en)	2014-03-24	2018-06-19	Xenoport, Inc.	Pharmaceutical compositions of fumaric acid esters
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US20170042880A1 (en)	2014-04-25	2017-02-16	Exelixis, Inc.	Method of Treating Lung Adenocarcinoma
TW201625247A (zh)	2014-05-12	2016-07-16	葛蘭素史密斯克藍智慧財產權有限公司	用於治療傳染性疾病之醫藥組合物
EP3151920A4 (en)	2014-06-04	2017-12-27	Sanford-Burnham Medical Research Institute	Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
US9526734B2 (en)	2014-06-09	2016-12-27	Iceutica Pty Ltd.	Formulation of meloxicam
WO2015195673A2 (en)	2014-06-18	2015-12-23	Demerx, Inc.	Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
US10654843B2 (en)	2014-06-20	2020-05-19	Principia Biopharma Inc.	LMP7 inhibitors
MA40219B1 (fr)	2014-06-25	2021-08-31	Glaxosmithkline Ip Dev Ltd	Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
DK3174535T3 (da) *	2014-08-01	2019-05-13	Glenmark Pharmaceuticals Sa	Nanopartikelformulering, der omfatter en mpges-1-hæmmer
US10016415B2 (en) *	2014-08-18	2018-07-10	Alkermes Pharma Ireland Limited	Aripiprazole prodrug compositions
CN106794251B (zh) *	2014-08-18	2020-12-29	阿尔科姆斯制药爱尔兰有限公司	阿立哌唑前体药物组合物
US20170246187A1 (en)	2014-08-28	2017-08-31	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en)	2014-08-28	2016-03-03	Lipocine Inc.	BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
AU2015311857A1 (en)	2014-09-03	2017-03-23	Genesegues, Inc.	Therapeutic nanoparticles and related compositions, methods and systems
JP2017527574A (ja)	2014-09-08	2017-09-21	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	２−（４−（４−エトキシ−６−オキソ−１，６−ジヒドロピリジン−３−イル）−２−フルオロフェニル）−ｎ−（５−（１，１，１−トリフルオロ−２−メチルプロパン−２−イル）イソオキサゾール−３−イル）アセトアミドの結晶形
DK3201203T3 (da)	2014-09-29	2021-08-23	Takeda Pharmaceuticals Co	Krystallinsk form af 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indol-3-carboxamid
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
US11311545B2 (en)	2014-10-09	2022-04-26	Board Of Regents Of The University Of Nebraska	Compositions and methods for the delivery of therapeutics
JP6716582B2 (ja)	2014-11-07	2020-07-01	サブリミティ・セラピューティクス・リミテッドＳｕｂｌｉｍｉｔｙＴｈｅｒａｐｅｕｔｉｃｓＬｉｍｉｔｅｄ	シクロスポリンを含む組成物
PL3223796T3 (pl) *	2014-11-25	2021-12-20	Curadigm Sas	Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania
MA41142A (fr)	2014-12-12	2017-10-17	Amgen Inc	Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
EP3256140B1 (en)	2015-01-09	2020-04-01	Etubics Corporation	Compositions for ebola virus vaccination
CN104587457B (zh) *	2015-01-13	2017-03-22	广东海大畜牧兽医研究院有限公司	一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法
US10166197B2 (en)	2015-02-13	2019-01-01	St. John's University	Sugar ester nanoparticle stabilizers
JP2018507209A (ja)	2015-02-20	2018-03-15	サイテックインダストリーズインコーポレイテッド	ジアルキルスルホスクシナート組成物、製造方法、および使用方法
IL315294A (en)	2015-03-03	2024-10-01	Pharmacyclics Llc	Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
EP3274053A4 (en)	2015-03-23	2018-12-05	The Brigham and Women's Hospital, Inc.	Tolerogenic nanoparticles for treating diabetes mellitus
CA3019769C (en)	2015-04-21	2021-10-12	Sunovion Pharmaceuticals Inc.	Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
WO2016183292A1 (en)	2015-05-14	2016-11-17	Longhorn Vaccines And Diagnostics, Llc	Rapid methods for the extraction of nucleic acids from biological samples
EP3298011B1 (en)	2015-05-22	2021-11-17	Principia Biopharma Inc.	Quinolone derivatives as fibroblast growth factor receptor inhibitors
PT3303334T (pt)	2015-06-03	2021-07-02	Principia Biopharma Inc	Inibidores da tirosina cinase
WO2016205423A2 (en)	2015-06-15	2016-12-22	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
MA42242A (fr)	2015-06-24	2018-05-02	Principia Biopharma Inc	Inhibiteurs de la tyrosine kinase
WO2017004610A1 (en)	2015-07-02	2017-01-05	Exelixis, Inc.	Tercyclic s1p3-sparing, s1p1 receptor agonists
ES2752455T3 (es)	2015-07-02	2020-04-06	Glaxosmithkline Ip Dev Ltd	Inhibidores de la indolamina 2,3-dioxigenasa
WO2017004608A1 (en)	2015-07-02	2017-01-05	Exelixis, Inc.	Oxadiazole modulators of s1p methods of making and using
WO2017004609A1 (en)	2015-07-02	2017-01-05	Exelixis, Inc.	Thiadiazole modulators of s1p and methods of making and using
US20180215781A1 (en)	2015-07-28	2018-08-02	Glaxosmithkline Intellectual Property (No.2) Limited	Betuin derivatives for preventing or treating hiv infections
WO2017017607A1 (en)	2015-07-28	2017-02-02	Glaxosmithkline Intellectual Property (No.2) Limited	Betuin derivatives for preventing or treating hiv infections
BR112018005870A2 (pt)	2015-09-24	2018-10-16	Glaxosmithkline Ip No 2 Ltd	composto, e, método de prevenção e/ou tratamento do hiv.
RU2018112958A (ru)	2015-09-24	2019-10-28	ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед	Соединения с ингибирующей созревание ВИЧ активностью
US10358427B2 (en)	2015-09-24	2019-07-23	Glaxosmithkline Intellectual Property Development Limited	Modulators of indoleamine 2,3-dioxygenase
MX2018004376A (es)	2015-10-16	2018-08-01	Marinus Pharmaceuticals Inc	Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
US10583140B2 (en)	2016-01-27	2020-03-10	Glaxosmithkline Intellectual Property Development Limited	Ingenol analogs, pharmaceutical compositions and methods of use thereof
WO2017142947A1 (en)	2016-02-17	2017-08-24	Global Blood Therapeutics, Inc.	Histone methyltransferase inhibitors
US10159671B2 (en)	2016-02-17	2018-12-25	Alkermes Pharma Ireland Limited	Compositions of multiple aripiprazole prodrugs
US10590084B2 (en)	2016-03-09	2020-03-17	Blade Therapeutics, Inc.	Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
GB201604124D0 (en)	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
JP7051721B2 (ja)	2016-06-30	2022-04-11	デュレクトコーポレーション	デポー製剤
US10682340B2 (en)	2016-06-30	2020-06-16	Durect Corporation	Depot formulations
US20190328900A1 (en)	2016-07-01	2019-10-31	Glaxosmithkline Intellectual Property Development Limited	Antibody-drug conjugates and therapeutic methods using the same
EP3481835A4 (en)	2016-07-05	2020-02-26	Blade Therapeutics, Inc.	CALPAIN MODULATORS AND THEIR THERAPEUTIC USES
AU2017311412B2 (en)	2016-08-11	2023-05-18	Ovid Therapeutics Inc.	Methods and compositions for treatment of epileptic disorders
MX2019001877A (es)	2016-08-19	2019-09-13	Orasis Pharmaceuticals Ltd	Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
US10391105B2 (en)	2016-09-09	2019-08-27	Marinus Pharmaceuticals Inc.	Methods of treating certain depressive disorders and delirium tremens
US10800773B2 (en)	2016-09-12	2020-10-13	Integral Health, Inc.	Monocyclic compounds useful as GPR120 modulators
AU2017326791B2 (en)	2016-09-13	2022-11-17	Kyowa Kirin Co., Ltd.	Medicinal composition
CN110023304A (zh)	2016-09-28	2019-07-16	布莱德治疗公司	钙蛋白酶调节剂及其治疗用途
MX375799B (es) *	2016-10-11	2025-03-07	Dsm Ip Assets Bv	Preparación de absorbedores de uv de tamaño nanométrico.
EP3538107A1 (en)	2016-11-10	2019-09-18	Boehringer Ingelheim International GmbH	Pharmaceutical composition, methods for treating and uses thereof
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
AU2017376431B2 (en)	2016-12-16	2022-01-27	Koppers Performance Chemicals Inc.	Wood preservative and method for producing same
US10829452B2 (en)	2016-12-22	2020-11-10	Global Blood Therapeutics, Inc.	Histone methyltransferase inhibitors
DK3571208T3 (da)	2017-01-18	2021-05-10	Principia Biopharma Inc	Immunproteasominhibitorer
CN116999564A (zh)	2017-04-10	2023-11-07	塞拉肿瘤学公司	抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法
CA3059631A1 (en)	2017-04-11	2018-10-18	Saje Pharma, Llc	Carbazole compounds and methods of use thereof
WO2018194283A1 (ko)	2017-04-21	2018-10-25	(주)바이오시네틱스	지질을 밀링 공정의 윤활제로 이용하는 활성물질 나노입자의 제조 방법
BR112019025770A2 (pt)	2017-06-09	2020-06-23	Global Blood Therapeutics, Inc.	Compostos de azaindol como inibidores de histona metiltransferase
SMT202400033T1 (it)	2017-07-14	2024-03-13	Janssen Pharmaceutica Nv	Formulazioni di bedaquilina ad azione prolungata
WO2019036377A1 (en)	2017-08-15	2019-02-21	Global Blood Therapeutics, Inc.	TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
WO2019036384A1 (en)	2017-08-15	2019-02-21	Global Blood Therapeutics, Inc.	TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
WO2019087016A1 (en)	2017-10-30	2019-05-09	Glaxosmithkline Intellectual Property Development Limited	Compounds useful in hiv therapy
WO2019099576A1 (en)	2017-11-16	2019-05-23	Principia Biopharma Inc.	Immunoproteasome inhibitors
AU2018367515B2 (en)	2017-11-16	2023-04-27	Principia Biopharma Inc.	Immunoproteasome inhibitors
CA3126348A1 (en)	2018-01-12	2020-07-18	Board Of Regents Of The University Of Nebraska	Antiviral prodrugs and formulations thereof
DE102018103528A1 (de)	2018-02-16	2019-08-22	Friedrich-Alexander-Universität Erlangen-Nürnberg	Suspension nanoskaliger, organischer Partikel und Verfahren zu ihrer Herstellung
WO2019169029A1 (en)	2018-02-28	2019-09-06	Bioxiness Pharmaceuticals, Inc.	Target specific chemotherapeutic agents
WO2019169017A1 (en)	2018-02-28	2019-09-06	Bioxiness Pharmaceuticals, Inc.	Chemotherapeutic agents
US20200407393A1 (en)	2018-03-07	2020-12-31	Glaxosmithkline Intellectual Property (No. 2) Limited	Medical Use
WO2019171174A2 (en) *	2018-03-07	2019-09-12	St Ip Holding Ag	Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
IL276911B2 (en)	2018-03-30	2025-04-01	Amgen Inc	Variants of the carboxylation rate of antibodies
CA3132832A1 (en)	2018-04-09	2019-10-17	Howard E. Gendelman	Antiviral prodrugs and formulations thereof
EP3804720A4 (en)	2018-06-11	2022-02-09	Otsuka Pharmaceutical Co., Ltd.	COMPOSITION CONTAINING DELAMANID
CN112040945A (zh)	2018-06-12	2020-12-04	Vtv治疗有限责任公司	葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
CA3107214A1 (en)	2018-07-20	2020-01-23	Lipocine Inc.	Liver disease
JP2021534112A (ja)	2018-08-09	2021-12-09	グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited	Ｈｉｖ療法に有用な化合物
WO2020041683A2 (en)	2018-08-23	2020-02-27	Sunovion Pharmaceuticals Inc.	Acid addition salts of apomorphine, pharmaceutical compositions containing the same, and methods of using the same
WO2020044257A1 (en)	2018-08-30	2020-03-05	Glaxosmithkline Intellectual Property (No.2) Limited	Compounds useful in hiv therapy
WO2020121006A2 (en)	2018-10-19	2020-06-18	Innostudio Inc.	Method and apparatus to produce nanoparticles in an ostwald ripening flow device with tubes of variable path length
AR117206A1 (es)	2018-11-30	2021-07-21	Glaxosmithkline Ip Dev Ltd	Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer
US11266662B2 (en)	2018-12-07	2022-03-08	Marinus Pharmaceuticals, Inc.	Ganaxolone for use in prophylaxis and treatment of postpartum depression
PH12021551760A1 (en)	2019-01-22	2022-05-30	The Roskamp Inst	Amino acid derivatives for the treatment of inflammatory diseases
EP3924386A4 (en)	2019-02-13	2023-01-04	The Brigham & Women's Hospital, Inc.	ADDRESSIN-TYPE ANTI-PERIPHERAL LYMPHATIC NODE ANTIBODIES AND THEIR USES
JP2022525013A (ja)	2019-03-06	2022-05-11	グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド	Ｈｉｖ療法において有用な化合物
EP4249070A3 (en)	2019-04-12	2024-04-17	Riboscience LLC	Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
JP2022543837A (ja)	2019-08-05	2022-10-14	マリナスファーマシューティカルズ，インコーポレイテッド	てんかん重積状態の治療に使用するためのガナキソロン
JP2022543319A (ja)	2019-08-08	2022-10-11	グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド	Ｈｉｖ治療に有用な化合物
EP4021916A1 (en)	2019-08-28	2022-07-06	GlaxoSmithKline Intellectual Property (No. 2) Limited	4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
WO2021072325A1 (en)	2019-10-11	2021-04-15	Corbus Pharmaceuticals, Inc.	Compositions of ajulemic acid and uses thereof
CA3158280A1 (en)	2019-12-06	2021-06-10	Alex Aimetti	Ganaxolone for use in treating tuberous sclerosis complex
JP2023510604A (ja)	2020-01-20	2023-03-14	ジェンザイム・コーポレーション	再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤
KR20220158031A (ko)	2020-03-26	2022-11-29	피엘엑스 옵코 인코포레이티드	pH 의존성 재구성이 가능한 제약 담체 및 그의 제조 및 사용 방법
CA3173330A1 (en)	2020-04-17	2021-10-21	Genzyme Corporation	Eclitasertib for use in treating conditions involving systemichyperinflammatory response
KR20230015346A (ko)	2020-04-22	2023-01-31	프린시피아 바이오파마, 인코퍼레이티드	Btk 억제제를 사용하는 급성 호흡 곤란 증후군 및 시토카인 폭풍을 수반하는 다른 장애의 치료
DK3928772T3 (da)	2020-06-26	2024-08-19	Algiax Pharmaceuticals Gmbh	Nanopartikulær sammensætning
PE20231296A1 (es)	2020-07-09	2023-08-22	Janssen Pharmaceutica Nv	Formulaciones a largo plazo
JP2023532981A (ja)	2020-07-09	2023-08-01	ヤンセンファーマシューティカエヌ．ベー．	長時間作用型配合物
US20230355606A1 (en)	2020-07-09	2023-11-09	Janssen Pharmaceutica Nv	Long-acting formulations
US11980636B2 (en)	2020-11-18	2024-05-14	Jazz Pharmaceuticals Ireland Limited	Treatment of hematological disorders
CN112451520B (zh) *	2020-12-31	2021-10-15	江苏宇锐医药科技有限公司	一种缬沙坦氨氯地平组合物及其制备方法
WO2022182604A1 (en)	2021-02-23	2022-09-01	Viiv Healthcare Company	Compounds useful in hiv treatment
WO2023023473A1 (en)	2021-08-16	2023-02-23	Sierra Oncology, Inc.	Methods of using momelotinib to treat chronic kidney disease
CA3230398A1 (en) *	2021-08-31	2023-03-09	Natsar Pharmaceuticals, Inc.	Intravenous formulations of rk-33
WO2023239727A1 (en)	2022-06-06	2023-12-14	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Lats inhibitors and uses thereof
WO2023244672A1 (en)	2022-06-14	2023-12-21	Assembly Biosciences, Inc.	2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections
EP4547249A1 (en)	2022-06-30	2025-05-07	Principia Biopharma Inc.	Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis
WO2024010782A1 (en)	2022-07-06	2024-01-11	Vividion Therapeutics, Inc.	Pharmaceutical compositions comprising wrn helicase inhibitors
MA71392A (fr)	2022-07-06	2025-04-30	Vividion Therapeutics, Inc.	Compositions pharmaceutiques comprenant des inhibiteurs de l'hélicase wrn
WO2024068693A1 (en)	2022-09-28	2024-04-04	Janssen Pharmaceutica Nv	Long-acting formulations
WO2024068699A1 (en)	2022-09-28	2024-04-04	Janssen Pharmaceutica Nv	Long-acting formulations
KR20250084183A (ko)	2022-10-11	2025-06-10	프린시피아 바이오파마, 인코퍼레이티드	다발성 경화증에 대한 치료용 티로신 키나제 저해제
CN115844821B (zh) *	2023-01-03	2024-05-17	江苏知原药业股份有限公司	一种地奈德纳米晶混悬液、制备方法及其应用
WO2025128898A1 (en)	2023-12-13	2025-06-19	Assembly Biosciences, Inc.	Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections
WO2025144874A1 (en)	2023-12-24	2025-07-03	The Roskamp Institute	Potent nf-kb inhibitors for the treatment of inflammatory diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2671750A (en) *	1950-09-19	1954-03-09	Merck & Co Inc	Stable noncaking aqueous suspension of cortisone acetate and method of preparing the same
US3192118A (en) *	1964-04-23	1965-06-29	Fmc Corp	Cellulose crystallites radiopaque media
US4107288A (en) *	1974-09-18	1978-08-15	Pharmaceutical Society Of Victoria	Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DK143689C (da) *	1975-03-20	1982-03-15	J Kreuter	Fremgangsmaade til fremstilling af en adsorberet vaccine
DE3013839A1 (de) *	1979-04-13	1980-10-30	Freunt Ind Co Ltd	Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
SE8204244L (sv) *	1982-07-09	1984-01-10	Ulf Schroder	Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
US4826689A (en) *	1984-05-21	1989-05-02	University Of Rochester	Method for making uniformly sized particles from water-insoluble organic compounds
CA1264566A (en) *	1984-09-05	1990-01-23	Tetsuji Iwasaki	Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder
GB8601100D0 (en) *	1986-01-17	1986-02-19	Cosmas Damian Ltd	Drug delivery system
NL194638C (nl) *	1986-12-19	2002-10-04	Novartis Ag	Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
DE3722837A1 (de) *	1987-07-10	1989-01-19	Ruetgerswerke Ag	Ophthalmisches depotpraeparat
JP2773895B2 (ja) *	1989-04-25	1998-07-09	東京田辺製薬株式会社	ダナゾール組成物
SE464743B (sv) *	1989-06-21	1991-06-10	Ytkemiska Inst	Foerfarande foer framstaellning av laekemedelspartiklar
JP2642486B2 (ja) *	1989-08-04	1997-08-20	田辺製薬株式会社	難溶性薬物の超微粒子化法
FR2660556B1 (fr) *	1990-04-06	1994-09-16	Rhone Poulenc Sante	Microspheres, leur procede de preparation et leur utilisation.

1991
- 1991-01-25 US US07/647,105 patent/US5145684A/en not_active Expired - Lifetime
1992
- 1992-01-15 CA CA002059432A patent/CA2059432C/en not_active Expired - Lifetime
- 1992-01-20 DE DE69231345T patent/DE69231345T2/de not_active Revoked
- 1992-01-20 ES ES92200153T patent/ES2149164T3/es not_active Expired - Lifetime
- 1992-01-20 EP EP92200153A patent/EP0499299B1/en not_active Revoked
- 1992-01-20 DK DK92200153T patent/DK0499299T3/da active
- 1992-01-20 SG SG1996006361A patent/SG55104A1/en unknown
- 1992-01-20 AT AT92200153T patent/ATE195416T1/de not_active IP Right Cessation
- 1992-01-20 PT PT92200153T patent/PT499299E/pt unknown
- 1992-01-22 NZ NZ241362A patent/NZ241362A/xx not_active IP Right Cessation
- 1992-01-23 MX MX9200291A patent/MX9200291A/es unknown
- 1992-01-24 MY MYPI92000109A patent/MY108134A/en unknown
- 1992-01-24 HU HU9200226A patent/HU221586B/hu unknown
- 1992-01-24 TW TW081100510A patent/TW247275B/zh not_active IP Right Cessation
- 1992-01-24 RU SU925010891A patent/RU2066553C1/ru active
- 1992-01-24 FI FI920321A patent/FI108333B/fi active
- 1992-01-24 IE IE021792A patent/IE920217A1/en not_active IP Right Cessation
- 1992-01-24 NO NO920334A patent/NO303668B1/no not_active IP Right Cessation
- 1992-01-24 IL IL10075492A patent/IL100754A/en not_active IP Right Cessation
- 1992-01-24 JP JP01122692A patent/JP3602546B2/ja not_active Expired - Lifetime
- 1992-01-25 KR KR1019920001077A patent/KR100200061B1/ko not_active Expired - Lifetime
2000
- 2000-11-07 GR GR20000402448T patent/GR3034759T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69231345D1 (de)	2000-09-21
IL100754A (en)	1996-10-16
NO920334L (no)	1992-07-27
JPH04295420A (ja)	1992-10-20
DE69231345T2 (de)	2001-04-26
RU2066553C1 (ru)	1996-09-20
EP0499299A3 (en)	1993-03-03
KR920014468A (ko)	1992-08-25
IL100754A0 (en)	1992-09-06
FI920321L (fi)	1992-07-26
DK0499299T3 (da)	2001-01-02
EP0499299A2 (en)	1992-08-19
GR3034759T3 (en)	2001-02-28
CA2059432A1 (en)	1992-07-26
MX9200291A (es)	1992-10-01
KR100200061B1 (ko)	1999-06-15
FI920321A0 (fi)	1992-01-24
HU9200226D0 (en)	1992-04-28
NO920334D0 (no)	1992-01-24
HU221586B (hu)	2002-11-28
ATE195416T1 (de)	2000-09-15
US5145684A (en)	1992-09-08
ES2149164T3 (es)	2000-11-01
PT499299E (pt)	2001-01-31
HUT62462A (en)	1993-05-28
NO303668B1 (no)	1998-08-17
NZ241362A (en)	1993-06-25
JP3602546B2 (ja)	2004-12-15
MY108134A (en)	1996-08-15
FI108333B (fi)	2002-01-15
AU654836B2 (en)	1994-11-24
EP0499299B1 (en)	2000-08-16
IE920217A1 (en)	1992-07-29
AU1014792A (en)	1992-07-30
SG55104A1 (en)	1998-12-21
CA2059432C (en)	2003-03-18

Publication	Publication Date	Title
TW247275B (zh)	1995-05-11
GR3022880T3 (en)	1997-06-30	Surface modified nsaid nanoparticles.
DK0577215T3 (da)	2000-08-28	Fremgangsmåde til fremstilling af overflademodificerede anticancer-nanopartikler
EP0319557A4 (en)	1991-05-08	Reconstituted hdl particles and uses thereof
AU4245289A (en)	1990-04-05	Psyllium-containing products
CA2111758A1 (en)	1994-06-19	Personal Care Compositions
AU4189293A (en)	1994-01-13	A psyllium-hydrocolloid gum composition
WO1994013304A3 (en)	1994-09-01	Antacid composition and method of production

Legal Events

Date	Code	Title	Description
2012-03-01	MK4A	Expiration of patent term of an invention patent